Clck to enlarge and view details
US PROVISIONAL PATENT APPLICATIONS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED IN 2011
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included drugs, medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors,
heparin, warfarin and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly
relevant documents.

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US PATENT APPLICATIONS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2011



Application No.: US20110002526A1  Published: 06/Jan/2011

Title: Method and Apparatus for Counting Thrombocytes

Applicant/Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIESALTERNATIVES

Application No.: 12/769057   Filing Date: 28/Apr/2010

Abstract:

A method of counting thrombocytes contained in a sample of blood, the method having the steps: mixing said sample with: fluorescent markers suitable for bonding specifically with the thrombocytes

and an agent for inhibiting activation of said thrombocytes

introducing the sample (E) into a fluidic chamber (CF) having at least one transparent face

acquiring at least one digital image (IN) of said sample by fluorescence microscopy under stationary illumination

and counting the thrombocytes (T) present in said or each image by image processing computer means (O). Apparatus for implementing the method.

Priority: FR20090002087 Applic. Date: 2009-04-29

Inventor: FAIVRE MAGALIE [FR]; CAILLAT PATRICE [FR]; CUBIZOLLES MYRIAM-LAURE [FR]; PEPONNET CHRISTINE [FR]; VAUCHIER CLAUDE [FR]


Application No.: US20110003294A1  Published: 06/Jan/2011

Title: Method of profiling gene expression in a healthy subject

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757918   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587384 Applic. Date: 2009-10-06; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110003295A1  Published: 06/Jan/2011

Title: Method of profiling gene expression in a subject undergoing a treatment

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757921   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587384 Applic. Date: 2009-10-06; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110003296A1  Published: 06/Jan/2011

Title: Method for the detection of gene transcripts in blood and uses thereof

Applicant/Assignee:

Application No.: 12/757928   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587382 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110003297A1  Published: 06/Jan/2011

Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757930   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-573863 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110003298A1  Published: 06/Jan/2011

Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757931   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-573856 Applic. Date: 2009-10-05; US2006-568730 Applic. Date: 2006-02-17; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110003826A1  Published: 06/Jan/2011

Title: ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION

Applicant/Assignee: OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYU "BIO

Application No.: 12/666250   Filing Date: 27/Jun/2008

Abstract:

This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery

and for preventing hypercoagulation conditions in consequence of injuries, surgeries, sepsis, various obstetric pathologies, in disaster medicine, resuscitation, and so on.

Priority: RU20070124202 Applic. Date: 2007-06-28; WO2008RU00401 Applic. Date: 2008-06-27

Inventor: SINAURIDZE ELENA IVANOVNA [RU]; ATAULLAKHANOV FAZOIL INOYATOVICH [RU]; BUTYLIN ANDREY ALEXANDROVICH [RU]; SULIMOV VLADIMIR BORISOVICH [RU]; ROMANOV ALEXEY NICKOLAYEVICH [RU]; BOGOLYUBOV ALEXEY ALEXEEVICH [RU]; KUZNETSOV YURY VLADIMIROVICH [RU]; GRIBKOVA IRINA VLADIMIROVNA [RU]; GORBATENKO ALEXANDER SERGEEVICH [RU]; KONDAKOVA OLGA ANATOLIEVNA [RU]


Application No.: US20110004300A1  Published: 06/Jan/2011

Title: PERCUTANEOUS AORTIC VALVE

Applicant/Assignee:

Application No.: 12/880456   Filing Date: 13/Sep/2010

Abstract:

The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood. In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority: US2008-288620 Applic. Date: 2008-10-22; US2005-222570 Applic. Date: 2005-09-09; US2003-429536 Applic. Date: 2003-05-05

Inventor: MCGUCKIN JR JAMES F [US]; HINCHLIFFE PETER W J [US]


Application No.: US20110008448A1  Published: 13/Jan/2011

Title: Diketopiperazine Salts for Drug Delivery and Related Methods

Applicant/Assignee: MANNKIND CORPORATION

Application No.: 12/886226   Filing Date: 20/Sep/2010

Abstract:

Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.

Priority: US2005-210710 Applic. Date: 2005-08-23; US20040603761P Applic. Date: 2004-08-23

Inventor: LEONE-BAY ANDREA [US]; MOYE-SHERMAN DESTARDI [US]; WILSON BRYAN R [US]


Application No.: US20110008779A1  Published: 13/Jan/2011

Title: Method of profiling gene expression in a subject having disease

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757914   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587384 Applic. Date: 2009-10-06; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110008780A1  Published: 13/Jan/2011

Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757925   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587385 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110008908A1  Published: 13/Jan/2011

Title: APPARATUS AND METHOD FOR SEPARATING AND ANALYZING BLOOD

Applicant/Assignee: MEDAVINCI DEVELOPMENT B.V

Application No.: 12/526394   Filing Date: 08/Feb/2008

Abstract:

An apparatus, comprising at least separating means (1) for separating blood plasma and red blood cells, which separating means (1) comprise pressure means (20) for pressing at least a part of the blood through a filter (26), wherein at least first collecting means (27) are provided for collecting separated blood plasma and at least one reagent is provided in said first collecting means (27) or can be introduced therein for reaction with substances or organisms present in said blood plasma.

Priority: NL20071033365 Applic. Date: 2007-02-09; WO2008NL50072 Applic. Date: 2008-02-08

Inventor: BIESBROUCK GERARDUS MAJELLA [NL]


Application No.: US20110009389A1  Published: 13/Jan/2011

Title: IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/879798   Filing Date: 10/Sep/2010

Abstract:

There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, -S(O)-, -S(O)2- or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z1 and Z3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z2 represents -N(R1)-, -O-, -S(O)-, -S(O)2-, -CO-, -CH(R1)- or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R1 to form an optionally substituted ring, and a represents 0, 1 or 2.

Priority: JP20020338939 Applic. Date: 2002-11-22; US2003-535268 Applic. Date: 2003-11-20; WO2003JP14793 Applic. Date: 2003-11-20

Inventor: KUBO KEIJI [JP]; KUROITA TAKANOBU [JP]; IMAEDA YASUHIRO [JP]; KAWAMURA MASAKI [JP]


Application No.: US20110009799A1  Published: 13/Jan/2011

Title: ANTITHROMBOGENIC HOLLOW FIBER MEMBRANES AND FILTERS

Applicant/Assignee: INTERFACE BIOLOGICS, INC

Application No.: 12/834730   Filing Date: 12/Jul/2010

Abstract:

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

Priority: US2010-780200 Applic. Date: 2010-05-14; US20090178861P Applic. Date: 2009-05-15

Inventor: MULLICK SANJOY [CA]; CHANG WEILUN [CA]; CHEN HANJE [CA]; STEEDMAN MARK [CA]; ESFAND ROSEITA [CA]


Application No.: US20110009955A1  Published: 13/Jan/2011

Title: COMPOUNDS AND METHOD FOR COATING SURFACES IN A HEMOCOMPATIBLE MANNER

Applicant/Assignee: HEMOTEQ GMBH

Application No.: 12/827710   Filing Date: 30/Jun/2010

Abstract:

The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.

Priority: DE20021021055 Applic. Date: 2002-05-10; US2004-513982 Applic. Date: 2004-11-08; WO2003DE01253 Applic. Date: 2003-04-15; US20020378676P Applic. Date: 2002-05-09

Inventor: HORRES ROLAND [DE]; LINSSEN MARITA KATHARINA [DE]; HOFFMANN MICHAEL [DE]; HOFFMANN ERIKA [DE]; DIBIASE DONATE [DE]; FAUST VOLKER [DE]


Application No.: US20110014614A1  Published: 20/Jan/2011

Title: Method of profiling gene expression in a subject having an infectious disease

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757934   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587385 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110017733A1  Published: 27/Jan/2011

Title: KIT FOR COLLECTING BLOOD, PREFERABLY PERIPHERAL BLOOD, FOR THE PRODUCTION OF STEM CELLS

Applicant/Assignee: SALES ENGINEERING AG

Application No.: 12/922498   Filing Date: 17/Mar/2009

Abstract:

A kit for collecting blood, preferably peripheral blood, for the production of pluripotent stem cells comprises at least a first container, able to contain the blood taken, which contains an anticoagulant and the substance MCSF (Macrophage Colony Stimulating Factor).

Priority: WO2009EP53144 Applic. Date: 2009-03-17; IT2008UD00058 Applic. Date: 2008-03-18

Inventor: POLETTINI MARCO [IT]; GAMBACURTA ALESSANDRA [IT]


Application No.: US20110020196A1  Published: 27/Jan/2011

Title: METHODS AND DEVICES FOR SEPARATING LIQUID COMPONENTS

Applicant/Assignee:

Application No.: 12/782617   Filing Date: 18/May/2010

Abstract:

Methods and devices for preparing a solid-fibrin web are provided. One method may include drawing blood from a patient, separating plasma from the blood, contacting the plasma with a calcium-coagulation activator and concurrently coagulating and axially centrifuging the plasma to form the solid-fibrin web. The solid-fibrin web may be suitable for regenerating body tissue in a living organism. Devices used in the methods may also be provided.

Priority: US2003-607580 Applic. Date: 2003-06-26; US20020392669P Applic. Date: 2002-06-27; US2002-053247 Applic. Date: 2002-01-15

Inventor: GRIPPI NICHOLAS A [US]; BERETTA ROBERTO C [IT]


Application No.: US20110020227A1  Published: 27/Jan/2011

Title: POLYSACCHARIDE-CONTAINING BLOCK COPOLMER PARTICLES AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS

Application No.: 12/820887   Filing Date: 22/Jun/2010

Abstract:

The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a diameter of about 1 to 1,000 nanometers, and methods of delivering agents or removing substances, e.g., undesirable substances, from a subject or environment, by using these particles.

Priority: US2002-324825 Applic. Date: 2002-12-19; US20010341980P Applic. Date: 2001-12-19; US20020424415P Applic. Date: 2002-11-07

Inventor: MCCARTHY STEPHEN P [US]; KOROSKENYI BALINT [US]; NICOLOSI ROBERT J [US]


Application No.: US20110020421A1  Published: 27/Jan/2011

Title: Biodegradable polyphosphazenes containing pyrrolidone side groups

Applicant/Assignee:

Application No.: 12/803908   Filing Date: 09/Jul/2010

Abstract:

Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.

Priority: US2007-974528 Applic. Date: 2007-10-12

Inventor: ANDRIANOV ALEXANDER K [US]; MARIN ALEXANDER [US]


Application No.: US20110020438A1  Published: 27/Jan/2011

Title: Crystallization Inhibitor and Its Use in Gelatin Capsules

Applicant/Assignee: IVAX PHARMACEUTICALS S.R.O

Application No.: 11/886500   Filing Date: 16/Mar/2006

Abstract:

The present invention describes soft gelatin capsules that encapsulate a water-insoluble active ingredient and an excipient composed of a crystallization inhibitor that stabilizes the water-insoluble inhibitor. The crystallization inhibitor being at least one mononacylglycerol compound whose acyl group is a fatty acid residue of 6-18 carbon atoms. The capsule contents are more resistant to turbidity, forming a coarse emulsion, and crystallization of the active ingredient compared with compositions absent the crystallization inhibitor.

Priority: US20050664826P Applic. Date: 2005-03-21; WO2006US09859 Applic. Date: 2006-03-16

Inventor: ANDRYSEK TOMAS [CZ]; VRANA ALES [CZ]


Application No.: US20110027771A1  Published: 03/Feb/2011

Title: METHODS AND COMPOSITIONS FOR CELL STABILIZATION

Applicant/Assignee: ARTEMIS HEALTH, INC

Application No.: 12/847876   Filing Date: 30/Jul/2010

Abstract:

Fragile cells have value for use in diagnosing many types of conditions. There is a need for compositions that stabilize fragile cells. The stabilization compositions of the provided invention allow for the stabilization, enrichment, and analysis of fragile cells, including fetal cells, circulating tumor cells, and stem cells.

Priority: US20090230638P Applic. Date: 2009-07-31

Inventor: DENG DAVID [US]


Application No.: US20110028903A1  Published: 03/Feb/2011

Title: BONE VOID FILLING TUBE AND SHEAR MECHANISM

Applicant/Assignee:

Application No.: 12/840931   Filing Date: 21/Jul/2010

Abstract:

Apparatus and methods for delivering a clotted biological component (such as blood, autologous conditioned plasma (ACP), platelet-rich plasma (PRP), bone marrow aspirate (BMA), demineralized bone matrix, anticoagulants and/or clotting agents, or combination of these materials) into a tissue void (for example, a bone void such as a bone tunnel, socket, opening or cavity), and then cutting the clotted biological component with a cutting or shearing mechanism at the tissue surface. The apparatus is provided with a tube and a cutting or shearing mechanism (provided on or within the distal end of the tube) that is actuated to cut or break off the clot at the desired insertion length. The tube may then be placed over the next tissue void so that the obturator drives the next clot into the next tissue void until all tissue voids are filled. Upon insertion at the defect site, the biological component advances the healing of the damaged tissue and tissue growth.

Priority: US20090229159P Applic. Date: 2009-07-28

Inventor: SCHMIEDING REINHOLD [US]; BENEDICT ROBERT [US]


Application No.: US20110041725A1  Published: 24/Feb/2011

Title: ANTICOAGULANTS AS ANTIFOULING AGENTS

Applicant/Assignee:

Application No.: 12/665505   Filing Date: 13/Jun/2008

Abstract:

Methods and compositions are provided for the reduction of fouling of objects present in marine environments. The methods and compositions include anticoagulants, such as, for example, glycosaminoglycans, coumarin-type molecules, metal chelators, plasminogen activators and platelet inhibitors. The methods include reducing marine fouling, comprising incorporating an anticoagulant compound into a marine coating. In addition, the methods include identifying compounds useful for reducing marine fouling, comprising measuring either blood coagulation or barnacle cement polymerization in the presence and absence of the compound, wherein a reduction in the blood coagulation or the barnacle cement polymerization in the presence of the compound identifies the compound as useful for reducing marine fouling. The coagulation or the polymerization can be measured by a serine protease activity or a transglutaminase activity.

Priority: US20070936284P Applic. Date: 2007-06-19; WO2008US07433 Applic. Date: 2008-06-13

Inventor: RITTSCHOF DANIEL [US]; DICKINSON GARY H [US]; ORIHUELA DE DIAZ BEATRIZ [US]; HOLM ERIC R [US]


Application No.: US20110052535A1  Published: 03/Mar/2011

Title: COMPOSITIONS FOR TREATING AN INFLAMMATORY AUTOIMMUNE CONDITION

Applicant/Assignee: TXCELL

Application No.: 12/989878   Filing Date: 08/Apr/2009

Abstract:

The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition.

Priority: EP20080305134 Applic. Date: 2008-04-28; US20080048298P Applic. Date: 2008-04-28; WO2009EP54228 Applic. Date: 2009-04-08

Inventor: FOUSSAT ARNAUD [FR]; BRUN VALERIE [FR]


Application No.: US20110053848A1  Published: 03/Mar/2011

Title: PRODRUG COMPRISING A DRUG LINKER CONJUGATE

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: 12/865693   Filing Date: 30/Jan/2009

Abstract:

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety

and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent

wherein L2 is a single chemical bond or a spacer

and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

Priority: EP20080150973 Applic. Date: 2008-02-01; EP20080170872 Applic. Date: 2008-12-05; WO2009EP51079 Applic. Date: 2009-01-30

Inventor: CLEEMANN FELIX [DE]; HERSEL ULRICH [DE]; KADEN SILVIA [DE]; RAU HARALD [DE]; WEGGE THOMAS [DE]


Application No.: US20110053933A1  Published: 03/Mar/2011

Title: HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 12/934506   Filing Date: 24/Mar/2009

Abstract:

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom

R3 represents a group such as a hydrogen atom

each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group

each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group

X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group [alpha]

Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

Priority: JP20080079919 Applic. Date: 2008-03-26; JP20080332106 Applic. Date: 2008-12-26; WO2009JP55741 Applic. Date: 2009-03-24

Inventor: MOTOKI KAYOKO [JP]; KAWAGOE KIICHI [JP]; NISHINAKA SHIGEYUKI [JP]; MASUDA SACHIE [JP]; SAKAMOTO ATSUNOBU [JP]; KANEKO SATORU [JP]; ARITA TSUYOSHI [JP]; YOKOMIZO AKI [JP]


Application No.: US20110054575A1  Published: 03/Mar/2011

Title: Methods and Apparatus for Regional and Whole Body Temperature Modification

Applicant/Assignee: ZOLL CIRCULATION INC

Application No.: 12/853864   Filing Date: 10/Aug/2010

Abstract:

Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region. Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US2007-931463 Applic. Date: 2007-10-31; US2007-724075 Applic. Date: 2007-03-13; US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1993-015714 Applic. Date: 1993-02-09

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]; GINSBURG ARIENE S [US]


Application No.: US20110059447A1  Published: 10/Mar/2011

Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757923   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-573856 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20110059460A1  Published: 10/Mar/2011

Title: Infection Mediated Foam Dissolution Rate Measurement

Applicant/Assignee: IMIGENE, INC

Application No.: 12/921021   Filing Date: 03/Mar/2009

Abstract:

The subject invention concerns methods and materials for determining the presence or absence of bacterial or fungal infection in a blood sample. In one embodiment, a method of the invention comprises exposing an anticoagulant treated blood sample to freezing the sample to a solid, followed by thawing of the sample and then agitation of the sample to develop foam and then observing the rate that foam dissolves.

Priority: US20080033166P Applic. Date: 2008-03-03; WO2009US35899 Applic. Date: 2009-03-03

Inventor: EWERT MATT [US]


Application No.: US20110059475A1  Published: 10/Mar/2011

Title: STABILISATION OF BLOOD CELL CONJUGATES

Applicant/Assignee: THE UNIVERSITY OF NOTTINGHAM

Application No.: 12/991477   Filing Date: 08/May/2009

Abstract:

The invention relates to methods and kits for stabilising blood cell conjugates in blood samples for subsequent analysis. The invention particularly relates to methods and kits for use in fixing and stabilising platelet aggregates in blood samples, and methods for detecting the degree of platelet aggregation in a sample. The invention extends to kits for monitoring the efficacy of anti-thrombotic treatment regimes using platelet aggregation analysis. Two compositions with aliphatic aldehydes and a buffer are employed in a consecutive order. The second composition comprises addition a chelating agent.

Priority: GB20080008413 Applic. Date: 2008-05-09; WO2009GB50482 Applic. Date: 2009-05-08

Inventor: MAY JANE ALISON [GB]; HEPTINSTAL STANLEY [GB]; FOX SUSAN CAROL [GB]


Application No.: US20110059547A1  Published: 10/Mar/2011

Title: USES OF REAGENTS IN SAMPLE COLLECTION AND CARTRIDGE SYSTEMS

Applicant/Assignee: ITI SCOTLAND LIMITED

Application No.: 12/933670   Filing Date: 20/Mar/2009

Abstract:

Provided is a sample collection container comprising one or more reagent bodies, wherein each body comprises one or more reagents confined by a restraining agent, wherein the restraining agent is capable of being broken down to release the one or more reagents, and wherein the one or more reagents are dispersed through the restraining agent. Further provided is a cartridge system comprising: (a) a reagent component for storing one or more reagents

and (b) a processing component for processing the one or more reagents in an assay

wherein one or more of the components comprise one or more reagent bodies, wherein each body comprises one or more reagents confined by a restraining agent, wherein the restraining agent is capable of being broken down to release the one or more reagents, and wherein the one or more reagents are dispersed through the restraining agent

and further wherein the reagent component and the processing component are configured to be coupled together to form a cartridge, and wherein the reagent component and/or the processing component comprise at least one compartment configured to accept waste from the assay, the reagent component not taking part in processing the reagents in the assay, except to accept waste from the processing component.

Priority: GB20080005296 Applic. Date: 2008-03-20; WO2009EP53327 Applic. Date: 2009-03-20

Inventor: DEHAL PRABHJYOT [GB]; PRITCHARD DAVID [GB]; GEEKIE CLAIRE [GB]


Application No.: US20110059958A1  Published: 10/Mar/2011

Title: MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS

Applicant/Assignee:

Application No.: 12/744736   Filing Date: 03/Dec/2009

Abstract:

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Priority: US20080120328P Applic. Date: 2008-12-05; US20090150955P Applic. Date: 2009-02-09; US20090165214P Applic. Date: 2009-03-31; US20090238455P Applic. Date: 2009-08-31; WO2009US66548 Applic. Date: 2009-12-03

Inventor: NISHIDA HIDEMITSU [JP]; SAITOH FUMIHIKO [JP]; HIRABAYASHI TOMOKAZU [JP]; CHACKALAMANNIL SAMUEL [US]; CHAN TIN-YAU [US]; CHELLIAH MARIAPPAN V [US]; CLASBY MARTIN C [US]; DWYER MICHAEL [US]; GREENLEE WILLIAM J [US]; XIA YAN [US]


Application No.: US20110060212A1  Published: 10/Mar/2011

Title: METHODS AND APPARATUS FOR FLOW RESTORATION

Applicant/Assignee: MICRO THERAPEUTICS, INC

Application No.: 12/918795   Filing Date: 20/Feb/2009

Abstract:

Methods for restoring blood flow in occluded blood vessels using an apparatus having a self expandable distal segment that is pre-formed to assume a superimposed structure in an unconstrained condition but can be made to take on a volume-reduced form making it possible to introduce it with a microcatheter and a push wire arranged at the proximal end, with the distal segment in its superimposed structure assuming the form of a longitudinally open tube and having a mesh structure of interconnected strings or filaments or struts. In a preferred embodiment, the distal segment has a tapering structure at its proximal end where the strings or filaments or struts converge at a connection point.

Priority: US20080030838P Applic. Date: 2008-02-22; WO2009US34774 Applic. Date: 2009-02-20

Inventor: SLEE EARL HOWARD [US]; WILDER III THOMAS [US]; MCCARTHY THOMAS [US]; FRANCO DAVID [US]; ASHBY MARK PHILIP [US]; SHRIVASTAVA SANJAY [US]


Application No.: US20110060578A1  Published: 10/Mar/2011

Title: COMPREHENSIVE MODELING OF THE HIGHLY NETWORKED COAGULATION-FIBRINOLYSIS-INFLAMMATORY-IMMUNE SYSTEM

Applicant/Assignee: VIRGINIA COMMONWEALTH UNIVERSITY

Application No.: 12/919529   Filing Date: 03/Mar/2009

Abstract:

An agent-based modeling system (ABMS) is employed to quantitatively analyze individual components of each system of the coagulation-immune/inflammatory-fibrinolysis system at every point of simulation. ABMS is a dynamic modeling and simulation tool that allows the study of dynamic non-linear networked systems. ABMS represents a non-reductionist approach of studying the biologic process as a whole, while retaining information at the level of an individual component.

Priority: US20080033138P Applic. Date: 2008-03-03; WO2009US35866 Applic. Date: 2009-03-03

Inventor: WARD KEVIN [US]; DESAI UMESH R [US]; MENKE NATHAN [US]; KIER LEMONT B [US]; CHENG C K [US]


Application No.: US20110071219A1  Published: 24/Mar/2011

Title: Hemostatic Effects of Glucono-Delta-Lactone

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: 12/851041   Filing Date: 05/Aug/2010

Abstract:

Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states.

Priority: US20090273589P Applic. Date: 2009-08-05

Inventor: SPILLERT CHARLES R [US]; PERSAUD DEBBIE [US]


Application No.: US20110073493A1  Published: 31/Mar/2011

Title: Adhesive Composition for Use in an Immunosensor

Applicant/Assignee: LIFESCAN, INC

Application No.: 12/570268   Filing Date: 30/Sep/2009

Abstract:

An adhesive composition for use in devices and methods for measuring a presence or a concentration of a particular component, such as an antigen, in a sample, such as blood, are provided. In one exemplary embodiment of an adhesive composition, the composition includes an adhesive, water, a poloxamer, and an anticoagulant. The adhesive can include particular properties, such as being hydrophilic, pressure-sensitive, heat-activated, and/or water soluble. The adhesive is particularly useful because it can help improve the flow of sample a device. For example, when the device is an immunosensor, the adhesive can help prevent the blood from clotting in chambers of the immunosensor. This results in a more efficient and accurate determination of the concentration of the sample. Methods of making the composition and device in which the composition can be used are provided, as are methods of using the same.

Priority:

Inventor: CHATELIER RONALD C [AU]; RYLATT DENNIS [AU]


Application No.: US20110076319A1  Published: 31/Mar/2011

Title: BIORESORBABLE METAL STENT WITH CONTROLLED RESORPTION

Applicant/Assignee:

Application No.: 12/524702   Filing Date: 30/Jan/2008

Abstract:

Embodiments herein relate to a special form of a bioresorbable metal stent with controlled resorption due to a wrap with a special polymer, thereby ensuring a controlled resorption of the wrapped endoprosthesis subsequent to its implantation into a blood vessel. The resorbable implant comprises a magnesium alloy provided with a biodegradable coating. The biodegradable coating comprises biodegradable polymers and can further include at least one pharmacologically active substance such as an antiproliferative, antimigrative, antiangiogenic, antiinflammatory, antiphlogistic, cytostatic, cytotoxic and/or antithrombotic agent, anti-restenosis agents, corticoids, sex hormones, statins, epothilones, prostacyclins and/or inductors of angiogenesis.

Priority: DE200710004589 Applic. Date: 2007-01-30; US20070899636P Applic. Date: 2007-02-06; WO2008DE00161 Applic. Date: 2008-01-30

Inventor: ORLOWSKI MICHAEL [DE]; RUEBBEN ALEXANDER [DE]


Application No.: US20110077971A1  Published: 31/Mar/2011

Title: Apparatus and Methods for Monitoring and Modifying Anticoagulation Therapy of Remotely Located Patients

Applicant/Assignee:

Application No.: 12/793029   Filing Date: 03/Jun/2010

Abstract:

A patient apparatus is configured to receive and analyze information regarding patient compliance with anticoagulation medication and self-test coagulation regimens related to anticoagulation therapy. In addition, a patient apparatus is configured to receive data from a patient, including physiological data, pathophysiological data, biological data, psychological data, neuropsychological data, and/or behavioral data. Utilizing the received patient data, a patient apparatus can modify a warfarin regimen using an algorithm contained within the apparatus. The apparatus can communicate the modified warfarin regimen to the patient and to third parties, such as remotely located healthcare providers. In addition, the apparatus can prompt a patient when to perform a self-test and can prompt a patient to seek immediate medical attention, or to directly contact medical help, when so warranted.

Priority: US2005-115824 Applic. Date: 2005-04-27; US2000-480432 Applic. Date: 2000-01-11

Inventor: SURWIT RICHARD S [US]; ALLEN III LYLE M [US]; MORRIS JR JAMES J [US]; ORTEL THOMAS LEE [US]


Application No.: US20110086008A1  Published: 14/Apr/2011

Title: COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES

Applicant/Assignee:

Application No.: 12/901293   Filing Date: 08/Oct/2010

Abstract:

The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2006-584870 Applic. Date: 2006-10-23; US2005-031325 Applic. Date: 2005-01-07; US2001-896912 Applic. Date: 2001-06-29; US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]


Application No.: US20110086363A1  Published: 14/Apr/2011

Title: Method and apparatus to conduct kinetic analysis of platelet function in whole blood samples

Applicant/Assignee:

Application No.: 12/923729   Filing Date: 05/Oct/2010

Abstract:

Adhesion of platelets to blood vessel walls is the first step that promotes arrest of bleeding by interaction of the platelet receptors with various extracellular matrix proteins that become exposed on vascular injury. A flow chamber is provided for use in analyzing or studying platelet function, in whole blood, either as part of a batch process or in real time. In the flow chambers, an inert polydimethylsiloxane (PDMS) surface is plasma-activated and a homobifunctional cross-linker is used to immobilize platelet-binding proteins onto a chamber wall surface. Immobilized collagen and fibrinogen may thus be assayed by continuously monitoring the adhesion of ADP and Ca2+ activated platelets from a subject, such as a patient having normal or type 2 diabetes (T2D). The flow chamber provides a simplified and robust method for the construction flow chambers which enable the kinetic monitoring of platelet adhesion in whole blood.

Priority: US20090272553P Applic. Date: 2009-10-06

Inventor: MUTUS BULENT [CA]; CARRIVEAU EDWARD C J [CA]; KAUR HARMANPREET [CA]


Application No.: US20110086847A1  Published: 14/Apr/2011

Title: THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/797457   Filing Date: 09/Jun/2010

Abstract:

The present invention relates to new thiadiazole modulators of beta adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20090186953P Applic. Date: 2009-06-15

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Application No.: US20110091433A1  Published: 21/Apr/2011

Title: TREATMENT USING REPROGRAMMED MATURE ADULT CELLS

Applicant/Assignee:

Application No.: 12/581362   Filing Date: 19/Oct/2009

Abstract:

A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.

Priority:

Inventor: ABULJADAYEL ILHAM MOHAMED SALEH SAEED [GB]


Application No.: US20110091570A1  Published: 21/Apr/2011

Title: Compositions and Devices for Antisepsis and Anticoagulation

Applicant/Assignee:

Application No.: 12/990381   Filing Date: 17/Mar/2009

Abstract:

Disclosed herein are compositions, methods, uses, and devices having antiseptic and anticoagulation properties in a mammal. The compositions, methods, uses, and devices are based on a therapeutically effective amount of one or more N-halogenated or N,N-dihalogenated amines, analogues or derivatives thereof, or pharmaceutically acceptable salts and esters. The preferred compound is N-chlorotaurine.

Priority: US20080045058P Applic. Date: 2008-04-15; WO2009IB00564 Applic. Date: 2009-03-17

Inventor: GOTTARDI WALDEMAR [AT]


Application No.: US20110091913A1  Published: 21/Apr/2011

Title: DRUG SAFETY TEST USING PENTRAXIN-3 (PTX-3)

Applicant/Assignee:

Application No.: 12/996642   Filing Date: 10/Jun/2009

Abstract:

The invention relates to an in vitro method for assessing the immunogenicity of a compound of interest comprising the steps of: a) providing a whole blood sample, wherein said blood was exposed to said compound of interest, b) measuring the level of pentraxin-3 in said sample, and c) comparing the measured level of pentraxin-3 with a control.

Priority: EP20080158724 Applic. Date: 2008-06-20; WO2009EP57146 Applic. Date: 2009-06-10

Inventor: KROPSHOFER HAROLD [DE]; PLOIX CORINNE [FR]; VOGT ANNE [DE]


Application No.: US20110091990A1  Published: 21/Apr/2011

Title: DEVICE AND METHODS FOR COLLECTION OF BIOLOGICAL FLUID SAMPLE AND TREATMENT OF SELECTED COMPONENTS

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 12/773525   Filing Date: 04/May/2010

Abstract:

A collection device and a method for collecting a biological sample, particularly whole blood, includes a separating member to separate the whole blood into its components, and at least reagent positioned to selectively interact with a component of the separated sample. The reagent is able to selectively interact with the plasma/serum, and is prevented from contacting or interacting with the whole blood.

Priority: US2004-912263 Applic. Date: 2004-08-05; US20030492313P Applic. Date: 2003-08-05

Inventor: DASTANE AJIT [US]; MANOUSSAKIS DIMITROIS [US]; BATTLES CHRISTOPHER [US]; DECESARE PAUL [US]; RADZIUNAS JEFFREY [US]


Application No.: US20110092576A1  Published: 21/Apr/2011

Title: SYNTHETIC PHOSPHODIESTER OLIGONUCLEOTIDES AND THERAPEUTICAL USES THEREOF

Applicant/Assignee: GENTIUM SPA

Application No.: 12/919605   Filing Date: 13/Mar/2009

Abstract:

A composition of phosphodiester oligonucleotides of various defined sizes has been created that mimics the effects of defibrotide. The composition essentially consists of mixtures of synthetic phosphodiester oligonucleotides comprising Nmers ranging from 40 mers to 65 mers. The phosphodiester oligonucleotides are preferably heteropolymers composed of either A, G, C, and T at each position but may also be homopolymers, i.e. the same base may be present at each position in the oligonucicotidc. These mixtures are effective in the treatment of cancer and other diseases.

Priority: EP20080425175 Applic. Date: 2008-03-19; US20080051088P Applic. Date: 2008-05-07; WO2009EP53002 Applic. Date: 2009-03-13

Inventor: STEIN AARON CY [US]; IACOBELLI MASSIMO [IT]


Application No.: US20110092953A1  Published: 21/Apr/2011

Title: Flowable Carrier Matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC, WARSAW OTHOPEDIC, INC

Application No.: 12/977310   Filing Date: 23/Dec/2010

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2009-634323 Applic. Date: 2009-12-09; US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20110098247A1  Published: 28/Apr/2011

Title: Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 12/912367   Filing Date: 26/Oct/2010

Abstract:

Compounds of formula I are provided: wherein Ar1 and Ar2 are substituted aromatic rings and L1 and L2 are independent divalent linking groups. The compounds are useful as platelet ADP receptor inhibitors, for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

Priority: US2007-856616 Applic. Date: 2007-09-17; US20060846328P Applic. Date: 2006-09-20

Inventor: SCARBOROUGH ROBERT M [US]; BAUER SHAWN M [US]; PANDEY ANJALI [US]; SCARBOROUGH CARROL ANNA CREW [US]


Application No.: US20110098345A1  Published: 28/Apr/2011

Title: Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics

Applicant/Assignee:

Application No.: 12/858369   Filing Date: 17/Aug/2010

Abstract:

The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Priority: US20090234939P Applic. Date: 2009-08-18; US20100353374P Applic. Date: 2010-06-10; US20100366362P Applic. Date: 2010-07-21; US20100367766P Applic. Date: 2010-07-26

Inventor: SCHAUB ROBERT G [US]; MCGINNESS KATHLEEN [US]; NELSON JENNIFER [US]; GENGA RYAN [US]; WATERS EMILY [US]; KURZ JEFFREY C [US]; DIENER JOHN L [US]


Application No.: US20110104709A1  Published: 05/May/2011

Title: POROUS SOLID PHASE FOR BINDING ASSAY, AND BINDING ASSAY METHOD USING THE SAME

Applicant/Assignee: SEKISUI MEDICAL CO., LTD

Application No.: 13/000110   Filing Date: 30/Jun/2009

Abstract:

A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant.

Priority: JP20080171367 Applic. Date: 2008-06-30; JP20090086378 Applic. Date: 2009-03-31; WO2009JP03038 Applic. Date: 2009-06-30

Inventor: YOSHIMIZU MIWAKO [JP]; KONDO MAYUMI [JP]; TANNO MASASHI [JP]


Application No.: US20110104725A1  Published: 05/May/2011

Title: Method of Effecting Coagulation in a Droplet

Applicant/Assignee: ADVANCED LIQUID LOGIC, INC, CHILDREN'S MEDICAL CENTER CORPORATION

Application No.: 12/990766   Filing Date: 04/May/2009

Abstract:

The invention provides techniques for coagulating blood on a droplet actuator. The invention also provides methods of manipulating the coagulated blood including a variety of droplet operations that may be conducted using the coagulated blood. Further, the invention provides a variety of assays that make use of the coagulated blood or various blood samples as input.

Priority: US20080049800P Applic. Date: 2008-05-02; US20080077184P Applic. Date: 2008-07-01; US20080091817P Applic. Date: 2008-08-26; US20080101321P Applic. Date: 2008-09-30; WO2009US42699 Applic. Date: 2009-05-04

Inventor: PAMULA VAMSEE K [US]; EMANI SITARAM [US]; ECKHARDT ALLEN [US]; GRAHAM CARRIE [US]; ROUSE JEREMY [US]


Application No.: US20110106136A1  Published: 05/May/2011

Title: IVC Filter With Drug Delivery

Applicant/Assignee: MEDTRONIC VASCULAR, INC

Application No.: 12/608217   Filing Date: 29/Oct/2009

Abstract:

Retrievable inferior vena cava filters are disclosed. Such filters provide for easy removal of the filter and provide drug delivery for dissolution of captured emboli. Methods of using such systems for the prevention, capture, dissolution and removal of emboli are described.

Priority:

Inventor: THOMPSON DUSTIN [US]; PERKINS D H [US]


Application No.: US20110110921A1  Published: 12/May/2011

Title: Methods for Treating Bleeding Disorders

Applicant/Assignee:

Application No.: 13/002501   Filing Date: 21/Aug/2009

Abstract:

A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor XI

and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor XI-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample

b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample

and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

Priority: US20080189734P Applic. Date: 2008-08-22; WO2009EP06082 Applic. Date: 2009-08-21

Inventor: DOCKAL MICHAEL [AT]; SCHEIFLINGER FRIEDRICH [AT]; TURECEK PETER [AT]


Application No.: US20110111476A1  Published: 12/May/2011

Title: BLOOD CELL SORTING METHODS AND SYSTEMS

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION

Application No.: 12/987575   Filing Date: 10/Jan/2011

Abstract:

The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.

Priority: US2006-646985 Applic. Date: 2006-12-28; US20050754426P Applic. Date: 2005-12-28

Inventor: FAUSTMAN DENISE L [US]; BURGER DOUGLAS E [US]


Application No.: US20110112083A1  Published: 12/May/2011

Title: FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

Applicant/Assignee: LEGOCHEM BIOSCIENCE LTD

Application No.: 13/002271   Filing Date: 05/Jun/2009

Abstract:

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

Priority: KR20080064178 Applic. Date: 2008-07-03; WO2009KR03008 Applic. Date: 2009-06-05

Inventor: SONG HO YOUNG [KR]; CHO YOUNG LAG [KR]; LEE DAE YON [KR]; PARK HEE SOCK [KR]; BAEK SUNG YOON [KR]; CHAE SANG EUN [KR]; JO SANG HUI [KR]; KIM YEON OK [KR]; LEE HYANG SOOK [KR]; PARK JU HYUN [KR]; PARK TAE KYO [KR]; WOO SUNG HO [KR]; KIM YONG ZU [KR]


Application No.: US20110117580A1  Published: 19/May/2011

Title: REDUCING LEUKOCYTE INTERFERENCE IN NON-COMPETITIVE IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/620179   Filing Date: 17/Nov/2009

Abstract:

The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads

and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; MOSS ADAM ROGER [CA]; DAVIS GRAHAM [US]


Application No.: US20110117581A1  Published: 19/May/2011

Title: REDUCING LEUKOCYTE INTERFERENCE IN COMPETITIVE IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/620230   Filing Date: 17/Nov/2009

Abstract:

The invention is directed to methods and devices for reducing interference from leukocytes in an competitive analyte immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads opsonized for leukocytes

and (b) performing a competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]


Application No.: US20110118173A1  Published: 19/May/2011

Title: METHOD OF DELIPIDATION OF HDL USING SERUM OPACITY FACTOR TO PREVENT, INHIBIT, AND/OR REVERSE ATHEROSCLEROSIS

Applicant/Assignee:

Application No.: 12/674469   Filing Date: 22/Aug/2008

Abstract:

This invention relates to delivering a therapeutically active serum opacity factor or an anti-atherosclerotic therapeutic lipoprotein generated from interaction with serum opacity factor to an individual that has or is at risk for atherosclerosis. This can be accomplished by in vivo or ex vivo delivery methods.

Priority: US20070957282P Applic. Date: 2007-08-22; WO2008US74027 Applic. Date: 2008-08-22

Inventor: POWNALL HENRY J [US]; COURTNEY HARRY S [US]


Application No.: US20110123414A1  Published: 26/May/2011

Title: MULTILAYER CONTAINERS

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 12/868234   Filing Date: 25/Aug/2010

Abstract:

A multilayer evacuated blood collection tube is provided having a first tube layer, and a second tube layer formed on the first tube layer and a closure, the second tube layer being a nanocomposite barrier layer. Such containers include but are not limited to blood collection tubes, evacuated blood collection tubes, centrifuge tubes, culture bottles, and syringe barrels.

Priority: US2004-480540 Applic. Date: 2004-07-02; US20010298957P Applic. Date: 2001-06-18

Inventor: AHERN BRIAN F [US]; CARANO DONALD J [US]; GRIPPI NICHOLAS A [US]; SOSKEY PAUL R [US]; LUSARDI GREGORY L [US]


Application No.: US20110125182A1  Published: 26/May/2011

Title: FILTER ELEMENT WITH RETRACTABLE GUIDEWIRE TIP

Applicant/Assignee: SALVIAC LIMITED

Application No.: 13/022040   Filing Date: 07/Feb/2011

Abstract:

A medical guidewire assembly comprises a guidewire having a flexible tip. A medical device such as a collapsible filter for use as an embolic protection device is mounted on the guidewire. The filter is advanced through a body lumen with the guidewire tip extending distally. A variable thickness guidewire (having a recess or thinner segment between thicker segments) can be employed. At a first location the filter is advanced relative to the tip to a location which is distally advanced from the first location. Placement of the filter in an optimal distal location is thereby achieved.

Priority: IE19970000789 Applic. Date: 1997-11-07; IE19980000267 Applic. Date: 1998-04-08; WO1999IE00039 Applic. Date: 1999-05-07; US2008-339375 Applic. Date: 2008-12-19; US2002-189375 Applic. Date: 2002-07-03; US2001-986060 Applic. Date: 2001-11-07; WO2000IE00057 Applic. Date: 2000-05-08; US1998-188472 Applic. Date: 1998-11-09

Inventor: BRADY EAMON [IE]


Application No.: US20110126303A1  Published: 26/May/2011

Title: Modified Blood Clotting Factors And Methods Of Use

Applicant/Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Application No.: 12/794215   Filing Date: 04/Jun/2010

Abstract:

The invention provides compositions including modified blood clotting factors that have a non-native proteolytic cleavage site engineered into them allowing intracellular cleavage and secretion of an active form. The compositions are useful in the methods for treating a bleeding or clotting disorder.

Priority: US2001-816688 Applic. Date: 2001-03-22; US20000191331P Applic. Date: 2000-03-22

Inventor: HIGH KATHERINE A [US]; MARGARITIS PARIS [US]; CAMIRE RODNEY [US]


Application No.: US20110129862A1  Published: 02/Jun/2011

Title: METHOD FOR DETERMINING CAUSE OF THE PROLONGATION OF BLOOD COAGULATION TIME

Applicant/Assignee: SEKISUI MEDICAL CO., LTD

Application No.: 12/999527   Filing Date: 16/Jun/2009

Abstract:

Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time. The method of determining a cause of the prolongation of blood coagulation time in test plasma includes (1) measuring the blood coagulation time of samples including (a) the test plasma only, (b) normal plasma only, and (c) the test plasma and the normal plasma mixed at least at a mixing ratio, (2) drawing a polygonal line graph by plotting the measurement results of the samples (a), (b) and (c), with the vertical axis representing the blood coagulation time or the prolongation ratio of blood coagulation time and the horizontal axis representing the mixing ratio or mixing proportion of the test plasma or the normal plasma, and thereby determining the area A under the polygonal line and the area B under a line segment that connects the plotted measurement results of the samples (a) and (b), (3) calculating the ratio of the area (A-B) obtained by subtracting the area B from the area A, with respect to the area B, ((A-B)/(B)):area ratio X), (4) performing the steps of (1) and (2) for a coagulation factor inhibitor-positive plasma, and thereby determining in advance a standard area ratio Y, and (5) comparing the area ratio X and the standard area ratio Y, and determining the test plasma as a coagulation factor inhibitor type in the case where Y!<=X, or as a coagulation factor deficient type in the case where Y>X.

Priority: JP20080159144 Applic. Date: 2008-06-18; WO2009JP02721 Applic. Date: 2009-06-16

Inventor: NAKAMURA REMI [JP]; MORIKAWA CHIZURU [JP]; SUNAGA HIROYUKI [JP]; YAGO HIROKAZU [JP]


Application No.: US20110133444A1  Published: 09/Jun/2011

Title: Color coded anatomical and non-anatomical sticker labels to be used on medication bottles to identify what medication is used for and when medication is due to be administered

Applicant/Assignee:

Application No.: 12/662454   Filing Date: 19/Apr/2010

Abstract:

Current medication labels are very difficult for people with disabilities, language barriers, functional impairments, or illiteracy to read, potentially increasing the risk for accidental medication overdoses and/or poor compliance with medication administration and adherence. By having a color coded sticker system with an enclosed full body guide in the form of a poster, and a home health medication record card, these stickers are placed on each medication bottle as a symbol for what the medication is used for. The stickers are color coded in order to distinguish the time the medication is to be administered. Home health agencies may use the poster and stickers as they educate their patients about the medications they take.

Priority: US20090267544P Applic. Date: 2009-12-08

Inventor: DOIRON WHITNEY [US]


Application No.: US20110135650A1  Published: 09/Jun/2011

Title: MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS

Applicant/Assignee:

Application No.: 12/791464   Filing Date: 01/Jun/2010

Abstract:

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Priority: US2010-744736 Applic. Date: 2010-05-26; WO2009US66548 Applic. Date: 2009-12-03; US20080120328P Applic. Date: 2008-12-05; US20090150955P Applic. Date: 2009-02-09; US20090165214P Applic. Date: 2009-03-31; US20090238455P Applic. Date: 2009-08-31

Inventor: CHACKALAMANNIL SAMUEL [US]; CHAN TIN-YAU [US]; CHELLIAH MARIAPPAN V [US]; CLASBY MARTIN C [US]; DWYER MICHAEL [US]; GREENLEE WILLIAM J [US]; HIRABAYASHI TOMOKAZU [JP]; NEELAMKAVIL SANTHOSH [US]; NISHIDA HIDEMITSU [JP]; SAITOH FUMIHIKO [JP]; SHAH UNMESH [US]; XIA YAN [US]


Application No.: US20110136861A1  Published: 09/Jun/2011

Title: QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/845384   Filing Date: 28/Jul/2010

Abstract:

The present invention relates to new quinolone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20090229025P Applic. Date: 2009-07-28

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Application No.: US20110137289A1  Published: 09/Jun/2011

Title: PORTABLE EQUIPMENT FOR ADMINISTRATION OF FLUIDS INTO TISSUES AND TUMORS BY CONVECTION ENHANCED DELIVERY TECHNIQUE

Applicant/Assignee: ANTISENSE PHARMA GMBH

Application No.: 13/027037   Filing Date: 14/Feb/2011

Abstract:

The present invention is directed to a device for a portable convection enhanced delivery system that allows administering liquids to specific locations within the body, especially tissues and tumors also allowing outsubject treatment. The application system comprises a portable extracorporal pump with a fluid reservoir that is connected via an infusion system to an infusion catheter placeable to any tissue or tumor the fluid should be administered to by high flow microperfusion. The system enables administration of fluids of any kind by convection enhanced delivery also in out-patient treatment. The system can be used for delivering various drugs, proteins, protein toxins, antibodies for treatment or imaging, proteins in enzyme replacement therapy, growth factors and viruses or oligonucleotides in gene therapy etc. The application methods as well as the surgical method to implant this device are enclosed to this invention.

Priority: US2003-420094 Applic. Date: 2003-04-22

Inventor: KUNST MECHTHILD [DE]


Application No.: US20110150938A1  Published: 23/Jun/2011

Title: Supercrystalline Colloidal Particles and Method of Production

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: 12/672447   Filing Date: 15/Aug/2008

Abstract:

The present invention concerns size- and shape-controlled, colloidal superparticles (SPs) and methods for synthesizing the same. Ligand-functionalized nanoparticles such as nonpolar-solvent-dispersible nanoparticles, are used, and the solvophobic interactions can be controlled. Advantageously, supercrystalline SPs having a superlattice structure, such as a face-centered cubic structure, can be produced. Further, the methods of the invention can provide SPs that self-assemble and are monodisperse. The SPs can be doped with organic dyes and further assembled into more complex structures.

Priority: US20070956625P Applic. Date: 2007-08-17; WO2008US73295 Applic. Date: 2008-08-15

Inventor: CAO Y CHARLES [US]; ZHUANG JIAQI [US]; WU HUIMENG [US]; YANG YONGAN [US]


Application No.: US20110151503A1  Published: 23/Jun/2011

Title: DEVICE AND METHOD FOR BACTERIOLOGICAL TESTING ON PLASMA

Applicant/Assignee: ALIFAX HOLDING SPA

Application No.: 13/060217   Filing Date: 19/Aug/2009

Abstract:

Apparatus for making a bacteriological test on plasma, comprising a sedimentation unit for a blood sample contained in a first container to separate the corpuscular part of the sample, which sediments on the bottom of the first container, from the liquid part or plasma, pick-up and inoculum means to pick up a portion of the surnatant, and to inoculate the portion in a culture ground inside a second container allowing a bacterial growth, optical measurement means, to effect measurements of the culture ground in order to determine the presence of bacteria and microorganisms, and processing means comprising a data bank, to collect measurement data, to construct a curve that represents the intensity of the radiation diverted by the culture ground in the measurement with respect to time, whose parameters are compared with reference values in order to determine typical analysis parameters, said values being characteristic for each bacterial species. Disclosed is further a corresponding method.

Priority: IT2008UD00190 Applic. Date: 2008-08-22; WO2009IB06588 Applic. Date: 2009-08-19

Inventor: GALIANO PAOLO [IT]


Application No.: US20110152719A1  Published: 23/Jun/2011

Title: MATERIALS AND METHODS FOR HYPOTHERMIC COLLECTION OF WHOLE BLOOD

Applicant/Assignee: BIOLIFE SOLUTIONS, INC

Application No.: 12/934644   Filing Date: 27/Mar/2009

Abstract:

The present invention relates to materials and methods for hypothermic collection of whole blood, and components thereof, which can extend the holding time of blood beyond the current useable limit. Additionally, blood can be drawn directly into a hypothermic preservation solution without the addition of standard anticoagulants. This is enabled by providing sustained cellular viability under hypothermic conditions using a nutrient matrix devoid of animal proteins and containing energy substrates, free-radical scavengers, and impermeants that is ionically balanced for storage of biologic materials at low temperatures to prevent cellular stress-induced apoptosis.

Priority: US20080039966P Applic. Date: 2008-03-27; US20080039978P Applic. Date: 2008-03-27; WO2009US38634 Applic. Date: 2009-03-27

Inventor: NICOUD IAN B [US]; CLARKE DOMINIC M [US]; MATHEW ABY J [US]; RICE MICHAEL [US]


Application No.: US20110155584A1  Published: 30/Jun/2011

Title: Systems, Devices, and Methods for Measuring Whole Blood Hematocrit Based on Initial Fill Velocity

Applicant/Assignee: LIFESCAN, INC

Application No.: 12/649509   Filing Date: 30/Dec/2009

Abstract:

Methods for determining the hematocrit of a blood sample, and devices and systems used in conjunction with the same. The hematocrit value can be determined on its own, and further, it can be further used to determine a concentration of an analyte in a sample. In one exemplary embodiment of a method for determining the hematocrit value in a blood sample, a volume of blood is provided in a sample analyzing device having a working and a counter electrode. An electric potential is applied between the electrodes and an initial fill velocity of the sample into the device is calculated. The hematocrit of the blood, as well as a concentration of an analyte in view of the initial fill velocity can then be determined. Systems and devices that take advantage of the use of an initial fill velocity to determine hematocrit levels and make analyte concentration determinations are also provided.

Priority:

Inventor: CHATELIER RONALD C [AU]; RYLATT DENNIS [AU]; RAINERI LINDA [AU]; HODGES ALASTAIR M [AU]


Application No.: US20110155585A1  Published: 30/Jun/2011

Title: Systems, Devices, and Methods for Improving Accuracy of Biosensors Using Fill Time

Applicant/Assignee: LIFESCAN, INC

Application No.: 12/649594   Filing Date: 30/Dec/2009

Abstract:

Methods for determining a concentration of an analyte in a sample, and the devices and systems used in conjunction with the same, are provided herein. In one exemplary embodiment of a method for determining a concentration of an analyte in a sample, a sample including an analyte is provided in a sample analyzing device having a working and a counter electrode. An electric potential is applied between the electrodes and a fill time of the sample into the device is calculated. A concentration of the analyte in view of fill time can then be determined. Systems and devices that take advantage of the fill time to make analyte concentration determinations are also provided.

Priority:

Inventor: CHATELIER RONALD C [AU]; HODGES ALASTAIR M [AU]


Application No.: US20110159597A1  Published: 30/Jun/2011

Title: ACTIVATED PARTIAL THROMBOPLASTIN TIME MEASURING REAGENT, ACTIVATED PARTIAL THROMBOPLASTIN TIME MEASURING METHOD, AND DETERMINATION METHOD FOR DETERMINING PRESENCE OR ABSENCE OF BLOOD COAGULATION INHIBITOR

Applicant/Assignee: SYSMEX CORPORATION

Application No.: 12/976681   Filing Date: 22/Dec/2010

Abstract:

An activated partial thromboplastin time measuring reagent, comprising a heparin neutralizer is disclosed. An activated partial thromboplastin time measuring method, and a determination method for determining a presence or absence of a blood coagulation inhibitor are also disclosed.

Priority: JP20090294107 Applic. Date: 2009-12-25

Inventor: YOSHIDA KAZUYO [JP]; OKUDA MASAHIRO [JP]


Application No.: US20110160614A1  Published: 30/Jun/2011

Title: BLOOD TEST APPARATUS

Applicant/Assignee: PANASONIC CORPORATION

Application No.: 13/043972   Filing Date: 09/Mar/2011

Abstract:

A blood sampling cartridge is attachable to and removable from an attaching part of a blood test apparatus that includes a housing. The attaching part is provided in one side of the housing. The blood sampling cartridge includes a holder, a blood sensor that is attachable to one end of the holder, a lancet that is movable inside the holder, a blood collection needle attached to one end of the lancet, and a guide provided on the lancet. The guide of the lancet is configured to latch with the holder after puncturing with the blood collection needle, such that the blood collection needle is prevented from projecting beyond the blood sensor.

Priority: JP20060000354 Applic. Date: 2006-01-05; JP20060000355 Applic. Date: 2006-01-05; JP20060000356 Applic. Date: 2006-01-05; JP20060000357 Applic. Date: 2006-01-05; JP20060000358 Applic. Date: 2006-01-05; JP20060022040 Applic. Date: 2006-01-31; US2008-159904 Applic. Date: 2008-07-02; WO2006JP326262 Applic. Date: 2006-12-28

Inventor: FUJIWARA MASAKI [JP]; AKIYAMA TOSHIHIRO [JP]; AMANO YOSHINORI [JP]


Application No.: US20110165251A1  Published: 07/Jul/2011

Title: LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 13/044450   Filing Date: 09/Mar/2011

Abstract:

The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.

Priority: US2003-619539 Applic. Date: 2003-07-16; US20020396530P Applic. Date: 2002-07-16

Inventor: BOSCH H WILLIAM [US]; HILBORN MATTHEW R [US]; HOVEY DOUGLAS C [US]; KLINE LAURA J [US]; LEE ROBERT W [US]; PRUITT JOHN D [US]; RYDE NIELS P [US]; RYDE TUULA A [US]; XU SHUQIAN [US]


Application No.: US20110165610A1  Published: 07/Jul/2011

Title: COMPOSITIONS, SYSTEMS, AND METHODS FOR PRESERVATION AND/OR STABILIZATION OF A CELL AND/OR MACROMOLECULE

Applicant/Assignee:

Application No.: 13/016706   Filing Date: 28/Jan/2011

Abstract:

The present disclosure relates to compositions, systems, and methods for preserving and/or stabilizing a cell (e.g., a whole cell). A cell and/or macromolecule stabilizing composition may include a chelator, a chelator enhancing component, and optionally a base (e.g., a purine base or a pyrimidine base). A cell stabilizing method may include contacting a cell with a cell and/or macromolecule stabilizing composition. A cell stabilizing system may include a container suitable for receiving a sample containing a cell and a cell and/or macromolecule stabilizing composition. A cell may be preserved and/or stabilized under ambient conditions (e.g., without refrigeration). A cell may include a protein, a nucleic acid, and/or another biomolecule marker of cell preservation and/or stabilization. A composition may be configured to preserve and/or stabilize one or more cells for analysis by flow cytometry and simultaneously preserve and/or stabilize one or more intracellular nucleic acids for molecular analysis.

Priority: US2008-048961 Applic. Date: 2008-03-14; US2007-686169 Applic. Date: 2007-03-14; WO2007US63982 Applic. Date: 2007-03-14; US20070894795P Applic. Date: 2007-03-14; US20070970881P Applic. Date: 2007-09-07; US20070983468P Applic. Date: 2007-10-29

Inventor: BAKER TONY [US]


Application No.: US20110172156A1  Published: 14/Jul/2011

Title: METHODS AND COMPOSITIONS FOR TREATING BLEEDING DISORDERS

Applicant/Assignee:

Application No.: 13/006396   Filing Date: 13/Jan/2011

Abstract:

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

Priority: US20100335964P Applic. Date: 2010-01-14

Inventor: DOCKAL MICHAEL [AT]; EHRLICH HARTMUT [AT]; SCHEIFLINGER FRIEDRICH [AT]


Application No.: US20110172583A1  Published: 14/Jul/2011

Title: HIGH CITRATE DIALYSATE AND USES THEREOF

Applicant/Assignee: ADVANCED RENAL TECHNOLOGIES

Application No.: 12/973598   Filing Date: 20/Dec/2010

Abstract:

The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5+-5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73+-5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23+-0.19 to 1.34+-0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCO3 may represent increased delivery from the dialysate and production from citric acid.

Priority: US2004-984374 Applic. Date: 2004-11-08; US2000-667489 Applic. Date: 2000-09-22; US19990155514P Applic. Date: 1999-09-22

Inventor: CALLAN ROBIN [US]; COLE JAMES J [US]


Application No.: US20110178137A1  Published: 21/Jul/2011

Title: DIARYL UREA FOR TREATING HEART FAILURE

Applicant/Assignee: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 13/001193   Filing Date: 16/Jun/2009

Abstract:

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing heart failure and/or connected diseases therewith comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.

Priority: EP20080011474 Applic. Date: 2008-06-25; WO2009EP04303 Applic. Date: 2009-06-16

Inventor: ALBRECHT-KUEPPER BARBARA [DE]; SCHAEFER STEFAN [DE]; KIENLEN ELODIE [DE]


Application No.: US20110178453A1  Published: 21/Jul/2011

Title: System and Method for Optimized Apheresis Draw and Return

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 13/076882   Filing Date: 31/Mar/2011

Abstract:

A blood processing device includes a venous-access device, a blood component separation device, a return line, a draw line, a first pressure sensor, a second pressure sensor, and a first pump. The first pressure sensor is located on the return line between the blood component separation device and the venous-access device, and determines a first pressure. The second pressure sensor is located on the draw line between the blood component separation device and the venous-access device, and determines a second pressure. The first pump is connected to at least one of the return line and the draw line and controls a flow rate within the connected line based on a subject access pressure determined based upon the first and second pressures.

Priority: US2008-102427 Applic. Date: 2008-04-14

Inventor: PAGES ETIENNE [FR]; RAGUSA MICHAEL [US]


Application No.: US20110182946A1  Published: 28/Jul/2011

Title: Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques

Applicant/Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 12/933405   Filing Date: 17/Mar/2009

Abstract:

The present invention provides a composition and method of forming an amorphous drug-loaded particle by forming one or more amorphous drug-loaded nanoparticles comprising one or more active agents stabilized by one or more polymers, desolvating the one or more amorphous drug-loaded nanoparticles to form one or more flocculated amorphous drug-loaded nanoparticles, filtering the one or more flocculated amorphous drug-loaded nanoparticles and drying the one or more flocculated amorphous drug-loaded nanoparticles to form amorphous drug-loaded particles.

Priority: US20080037213P Applic. Date: 2008-03-17; WO2009US37391 Applic. Date: 2009-03-17

Inventor: JOHNSTON KEITH P [US]; WILLIAMS III ROBERT O [US]; MATTEUCCI MICHAL E [US]


Application No.: US20110184316A1  Published: 28/Jul/2011

Title: PHLEBOTOMY DEVICE HAVING FLEXIBLE VALVE FOR DETECTING FLASHBACK

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 13/077179   Filing Date: 31/Mar/2011

Abstract:

A phlebotomy device includes a needle defining a lumen and having a proximal end portion and a distal end portion. The distal end portion includes a sharpened tip configured to pierce tissue. The phlebotomy device further includes a sensor disposed at least partially within the lumen. The sensor has a first state and a second state and is configured to transition from the first state to the second state upon exposure to blood at physiological temperature.

Priority: US2008-212184 Applic. Date: 2008-09-17; US20070995588P Applic. Date: 2007-09-27

Inventor: CHELAK TODD M [US]


Application No.: US20110189166A1  Published: 04/Aug/2011

Title: METHODS OF TREATING HEMORHEOLOGIC ABNORMALITIES IN MAMMALS

Applicant/Assignee:

Application No.: 13/016984   Filing Date: 29/Jan/2011

Abstract:

Methods of treating hemorheologic abnormalities in mammals are provided, as well as methods of evaluating circulatory flow mechanics by analyzing hemorheologic determinants or hemorheologic abnormalities in the blood.

Priority: US20100282377P Applic. Date: 2010-01-29

Inventor: BOUCHER JOHN [US]


Application No.: US20110190867A1  Published: 04/Aug/2011

Title: DIRECTIONAL EXPANSION OF INTRALUMINAL DEVICES

Applicant/Assignee:

Application No.: 13/061339   Filing Date: 27/Aug/2009

Abstract:

Methods and devices useful, for example, in the field of angioplasty and stenting are disclosed. In some embodiments, the methods, devices and kits are configured for directional expansion inside a lumen, for example of a blood vessel obstructed by plaque. In some embodiments, the directional expansion displaces the plaque in a desired direction.

Priority: US20080092561P Applic. Date: 2008-08-28; WO2009CA01198 Applic. Date: 2009-08-27

Inventor: VONDERWALDE CARLOS [CA]; PENA DUQUE MARCO ANTONIO [MX]


Application No.: US20110195437A1  Published: 11/Aug/2011

Title: METHOD FOR CHARACTERIZING, IN PARTICULAR FOR QUANTIFYING, MOLECULAR MARKERS THAT ARE INTRACELLULARLY ABSORBED FROM TISSUES BY BLOOD MACROPHAGES THAT ARE RECIRCULATED FROM THE TISSUES INTO THE CIRCULATORY SYSTEM

Applicant/Assignee: SYNMED RESEARCH GMBH

Application No.: 12/737598   Filing Date: 04/Aug/2009

Abstract:

The invention relates to a method for characterizing, in particular for quantifying molecular marker(s) that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into the circulatory system, wherein the following steps are carried out: application of an agent to whole blood, said agent inhibiting coagulation and/or agglomeration of whole blood

selecting and/or enriching and/or separating blood macrophages or leukocyte populations that contain blood macrophages from whole blood

perforating and/or lysing the selected blood macrophages or leukocyte populations containing the blood macrophages, optionally after previous permeabilization thereof

qualitatively and quantitatively determining non blood macrophage markers, namely molecular markers arising from tissue, after previously perforating and/or lysing the blood macrophages or leukocyte populations containing the blood macrophages, and an apparatus for carrying out the method.

Priority: DE200810036185 Applic. Date: 2008-08-04; WO2009EP60106 Applic. Date: 2009-08-04

Inventor: BROZEK WOLFGANG [AT]


Application No.: US20110196340A1  Published: 11/Aug/2011

Title: LOADING AND RELEASE OF WATER-INSOLUBLE DRUGS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 13/085623   Filing Date: 13/Apr/2011

Abstract:

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Priority: US2007-833717 Applic. Date: 2007-08-03; US2005-188850 Applic. Date: 2005-07-26; US2001-978763 Applic. Date: 2001-10-18; US1998-172026 Applic. Date: 1998-10-14; US1998-133603 Applic. Date: 1998-08-13; US1997-910136 Applic. Date: 1997-08-13

Inventor: BARRY JAMES J [US]; PALASIS MARIA [US]


Application No.: US20110200673A1  Published: 18/Aug/2011

Title: OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS

Applicant/Assignee:

Application No.: 13/029584   Filing Date: 17/Feb/2011

Abstract:

The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.

Priority: US2003-667216 Applic. Date: 2003-09-19; US20020411851P Applic. Date: 2002-09-20

Inventor: MOUSA SHAKER A [US]


Application No.: US20110201541A1  Published: 18/Aug/2011

Title: TISSUE OCCLUDING AGENT

Applicant/Assignee: 3-D MATRIX, LTD

Application No.: 13/122758   Filing Date: 06/Oct/2009

Abstract:

There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a [beta]-structure in aqueous solution in the presence of physiological pH and/or a cation.

Priority: JP20080259860 Applic. Date: 2008-10-06; JP20080316133 Applic. Date: 2008-12-11; WO2009JP67367 Applic. Date: 2009-10-06

Inventor: TAKAMURA KENTARO [JP]; GOJO SATOSHI [JP]; KOBAYASHI SATORU [JP]


Application No.: US20110201553A1  Published: 18/Aug/2011

Title: Systemic Pro-hemostatic Effect of Sympathicomimetics with Agonistic Effects on Alfa-Adrenergic and/or Beta-Adrenergic Receptors of the Sympathetic Nervous System, Related to Improved Clot Strength

Applicant/Assignee: HEMOSTATIS HOLDING APS

Application No.: 12/681352   Filing Date: 01/Oct/2008

Abstract:

The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

Priority: DK20070001418 Applic. Date: 2007-10-02; WO2008DK50242 Applic. Date: 2008-10-01

Inventor: JOHANSSON PAER [SE]; SECHER NIELS H [DK]; BOCHSEN LOUISE [DK]


Application No.: US20110206776A1  Published: 25/Aug/2011

Title: METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS

Applicant/Assignee:

Application No.: 13/030562   Filing Date: 18/Feb/2011

Abstract:

Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Priority: US20100338464P Applic. Date: 2010-02-18; US20100338489P Applic. Date: 2010-02-18; US20100369562P Applic. Date: 2010-07-30

Inventor: TOM SAMSON [US]; DANILKOVITCH ALLA [US]; YOO DANA [US]; JANSEN TIMOTHY [US]; KUANG JIN-QIANG [US]; MARCONI JENNIFER MICHELLE [US]


Application No.: US20110212063A1  Published: 01/Sep/2011

Title: METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS

Applicant/Assignee:

Application No.: 13/030539   Filing Date: 18/Feb/2011

Abstract:

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Priority: US20100338464P Applic. Date: 2010-02-18; US20100338489P Applic. Date: 2010-02-18; US20100369562P Applic. Date: 2010-07-30

Inventor: TOM SAMSON [US]; DANILKOVITCH ALLA [US]; YOO DANA [US]; JANSEN TIMOTHY [US]; KUANG JIN-QIANG [US]; MARCONI JENNIFER MICHELLE [US]


Application No.: US20110212930A1  Published: 01/Sep/2011

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 13/101536   Filing Date: 05/May/2011

Abstract:

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2010-691895 Applic. Date: 2010-01-22; US2009-401401 Applic. Date: 2009-03-10; US2007-955678 Applic. Date: 2007-12-13; US2005-198801 Applic. Date: 2005-08-05; US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20110213305A1  Published: 01/Sep/2011

Title: HEAT EXCHANGER AND METHOD FOR HEAT EXCHANGING

Applicant/Assignee: GRAMBRO LUNDIA AB

Application No.: 13/123008   Filing Date: 09/Oct/2009

Abstract:

A method for exchanging heat between a primary fluid (W) and a secondary fluid (X) and a heat exchanger for heat exchange as well as an arrangement and a kit comprising a heat exchanger. The heat exchanger comprises a first and a second fluid circuit extending through the heat exchanger. The heat exchanger further comprises a stack of fluid plates and a membrane arranged between each of the fluid plates where one interspace is formed between each fluid plate and membrane. The first and the second fluid circuit are each constituted by a passage extending through the fluid plates and membranes and along the fluid plates and membranes in at least two interspaces. A primary fluid (W) is passed through the first fluid circuit and a secondary fluid (X) is passed through the second fluid circuit such that the primary fluid (W) is passed along one side of a membrane and simultaneously the secondary fluid (X) is passed along the other side of the membrane. Heat is thus exchanged between the primary fluid (W) and the secondary fluid (X) over the membrane.

Priority: SE20080002131 Applic. Date: 2008-10-10; US20080104275P Applic. Date: 2008-10-10; WO2009EP63148 Applic. Date: 2009-10-09

Inventor: JOENSSON LENNART [SE]; STERNBY JAN [SE]; NILSSON EDDIE [SE]


Application No.: US20110217284A1  Published: 08/Sep/2011

Title: Factor IX Variants with Clotting Activity in Absence of Their Cofactor and Their Use for Treating Bleeding Disorders

Applicant/Assignee:

Application No.: 13/001187   Filing Date: 28/Jul/2009

Abstract:

The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.

Priority: EP20080013561 Applic. Date: 2008-07-28; WO2009EP05465 Applic. Date: 2009-07-28

Inventor: SEIFRIED ERHARD [DE]; SCHUETTRUMPF JOERG [DE]


Application No.: US20110217289A1  Published: 08/Sep/2011

Title: Melt-Coated Dosage Forms

Applicant/Assignee: BASF SE

Application No.: 13/040534   Filing Date: 04/Mar/2011

Abstract:

Formulations of sparingly water-soluble active ingredientscomprising carrier particles provided with active ingredient-containing coatings, the sparingly soluble active ingredients being embedded in coatings composed of amphiphilic copolymers, and the coatings being applied in the form of a solvent-free melt.

Priority: US20100310731P Applic. Date: 2010-03-05

Inventor: KOLTER KARL [DE]; DJURIC DEJAN [DE]


Application No.: US20110223579A1  Published: 15/Sep/2011

Title: Composition for Preserving Platelets and Method of Using the Same

Applicant/Assignee: BIOVEC TRANSFUSION, LLC

Application No.: 13/099061   Filing Date: 02/May/2011

Abstract:

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US2006-330132 Applic. Date: 2006-01-12; US20050643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]


Application No.: US20110223663A1  Published: 15/Sep/2011

Title: COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING THE SAME

Applicant/Assignee: BIOVEC TRANSFUSION, LLC

Application No.: 13/098128   Filing Date: 29/Apr/2011

Abstract:

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US2006-330132 Applic. Date: 2006-01-12; US20050643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]


Application No.: US20110224292A1  Published: 15/Sep/2011

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee:

Application No.: 12/932822   Filing Date: 07/Mar/2011

Abstract:

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents. One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

Priority: US2009-378456 Applic. Date: 2009-02-14

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Application No.: US20110224655A1  Published: 15/Sep/2011

Title: CENTRAL CORE MULTIFUNCTIONAL CARDIAC DEVICES

Applicant/Assignee:

Application No.: 13/063374   Filing Date: 11/Sep/2009

Abstract:

Intracardiac devices that can provide a plurality of functions (e.g., pacing, defibrillation, cardiac assist, or valve replacement) via a single support member and control means.

Priority: US20080096126P Applic. Date: 2008-09-11; WO2009US56690 Applic. Date: 2009-09-11

Inventor: ASIRVATHAM SAMUEL J [US]; BRUCE CHARLES J [US]; FRIEDMAN PAUL A [US]; SPEZIALI GIOVANNI [US]


Application No.: US20110230571A1  Published: 22/Sep/2011

Title: DIAGNOSTIC AND THERAPEUTIC PROTOCOLS

Applicant/Assignee: ALFRED HEALTH, MONASH UNIVERSITY

Application No.: 12/739698   Filing Date: 24/Oct/2008

Abstract:

The present invention relates to methods for determining co-receptor usage of an HIV in a subject including the steps of: culturing a viral preparation derived from the subject's plasma with one or more cell lines which express surface CD4 and CCR5, surface CD4 and CXCR4, or surface CD4, CCR5 and CXCR4, wherein an anticoagulant is added to the viral preparation or to the culture

and screening for infection, wherein the presence or absence of infected cells is indicative of the co-receptors used by the HIV.

Priority: US20070983062P Applic. Date: 2007-10-26; WO2008AU01578 Applic. Date: 2008-10-24

Inventor: LEWIN SHARON R [AU]; CORNALL ALYSSA MARIE [AU]; CAMERON PAUL URQUHART [AU]


Application No.: US20110236885A1  Published: 29/Sep/2011

Title: Genetic Variants Predicting Warfarin Sensitivity

Applicant/Assignee: ACADEMIA SINICA

Application No.: 12/722672   Filing Date: 12/Mar/2010

Abstract:

We discovered that a polymorphism in the promoter of the VKORC1 gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORC1 gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

Priority: US2005-316406 Applic. Date: 2005-12-21; US20050679694P Applic. Date: 2005-05-10; US20040638837P Applic. Date: 2004-12-21

Inventor: CHEN YUAN-TSONG [TW]; YUAN HSIANG-YU [TW]; CHEN JIN-JER [TW]


Application No.: US20110237512A1  Published: 29/Sep/2011

Title: Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides

Applicant/Assignee:

Application No.: 12/893798   Filing Date: 29/Sep/2010

Abstract:

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Priority: US2009-386026 Applic. Date: 2009-04-13; US2005-140504 Applic. Date: 2005-05-27; US20040574845P Applic. Date: 2004-05-27

Inventor: JOHNSON KIRK W [US]


Application No.: US20110237996A1  Published: 29/Sep/2011

Title: Methods of Regional Citrate Anticoagulation Dialysis

Applicant/Assignee: FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 12/817390   Filing Date: 17/Jun/2010

Abstract:

A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point.

Priority: US20090268871P Applic. Date: 2009-06-17; US20100335546P Applic. Date: 2010-01-08

Inventor: KOTANKO PETER [US]; THIJSSEN STEPHAN [US]; LEVIN NATHAN W [US]


Application No.: US20110245635A1  Published: 06/Oct/2011

Title: PRESSURE REDUCTION MECHANISM, PUNCTURE DEVICE, BLOOD ANALYSIS DEVICE, AND SENSOR MOUNTING MECHANISM

Applicant/Assignee: PANASONIC CORPORATION

Application No.: 13/133258   Filing Date: 15/Oct/2009

Abstract:

Provided are a decompression mechanism capable of performing a desired pressure reduction by simple operation and having improved operability, a puncture device, a blood analysis device, and a sensor mounting mechanism. A needle puncturing device (100) is provided with: a piston (121) having at one end thereof an end part (121a) for forming a part of a sensor mounting mechanism (130) and at the other end an end part (121b) for slidably supporting a rod (112) of a lancet section (111)

a cylinder (122) for slidably containing therein the end section (121b) of the piston (121)

and packing (125) mounted to the inner periphery of the end part (121b) of the piston (121) and maintaining the air-tightness of the outer periphery of the rod (112). When the piston (121) is moved in the direction toward the cylinder (122) with a skin contact part (131) in contact with the skin, the volumes of an internal space (140) and a pressure reduction chamber (150) which are sealed by packing (123, 124) are increased to produce a reduced pressure.

Priority: JP20080313644 Applic. Date: 2008-12-09; JP20080317341 Applic. Date: 2008-12-12; WO2009JP05380 Applic. Date: 2009-10-15

Inventor: FUJIWARA MASAKI [JP]; HASHIMOTO YOHEI [JP]


Application No.: US20110250134A1  Published: 13/Oct/2011

Title: SUSTAINED RELEASE NITRIC OXIDE FROM LONG LIVED CIRCULATING NANOPARTICLES

Applicant/Assignee:

Application No.: 13/086346   Filing Date: 13/Apr/2011

Abstract:

The invention provides methods for delivering a NO molecule or precursor thereof to a vascular compartment of a subject comprising: administering to the subject, a NO particle formulation, via an intravascular, intraperitoneal, or intramuscular administration, in an amount sufficient to induce vascular smooth muscle relaxation thereby delivering the NO molecule or precursor thereof to the vascular compartment of the subject, wherein the NO particle formulation comprises NO attached to a nanoparticle or microparticle.

Priority: US20100323832P Applic. Date: 2010-04-13

Inventor: CABRALES PEDRO [US]; FRIEDMAN ADAM [US]; FRIEDMAN JOEL M [US]


Application No.: US20110250256A1  Published: 13/Oct/2011

Title: Dissolvable Nano Web Porous Film and Method of Preparing the Same

Applicant/Assignee: GENIC CO, LTD

Application No.: 12/672950   Filing Date: 28/Jun/2011

Abstract:

A dissolvable nano web porous film has a network structure and a large specific surface area. The network structure is formed by stacking nano fibers that have a thickness of 10 (approx.) 50,000 nm. The nano fibers are formed of a composition comprising nano fiber forming polymer, a gelling agent, a plasticizer, an optional active component and an optional additive. A method of preparing a dissolvable nano web film comprises producing a polymer melt or solution formed of a composition that comprises a nano fiber forming polymer, a gelling agent, a plasticizer, an optional active component and additives, spinning the melt or solution to form a nano web porous film having nano webs stacked in a network structure, drying the nano web porous film, and stabilizing the nano web porous film. The porous film has a 5 (approx.) 5000 times higher specific surface area and a 2 (approx.) 20 times faster dissolving time than a conventional film. The dissolvable nano web porous film has excellent dissolvability and solubility.

Priority: KR20070080677 Applic. Date: 2007-08-10; WO2007KR04342 Applic. Date: 2007-09-07

Inventor: HYUN-OH YOO [KR]; TAE-WON SON [KR]


Application No.: US20110250287A1  Published: 13/Oct/2011

Title: One step removal of selected molecules from body fluid and tissue

Applicant/Assignee: ADVANCED EXTRAVASCULAR SYSTEMS, INC

Application No.: 12/803400   Filing Date: 25/Jun/2010

Abstract:

A method for reducing the number of selected antibodies in a subject's blood, the method comprising removing blood from the subject, passing the blood along an enclosed pathway, wherein the pathway comprises one or more semi-permeable hollow fibers with one or more membranes having surfaces positioned substantially perpendicular to the length of the one or more hollow fiber and antigens specific for the antibodies immobilized on the one or more membranes, returning the treated blood to the internal circulation of the subject, wherein the returned treated blood has a reduced number of selected antibodies compared to before treatment.

Priority: US2004-778662 Applic. Date: 2004-02-13; US2000-566510 Applic. Date: 2000-05-08

Inventor: BRISTOW DUKE K [US]


Application No.: US20110251160A1  Published: 13/Oct/2011

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/128463   Filing Date: 10/Nov/2009

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: US20080113413P Applic. Date: 2008-11-11; US20090237566P Applic. Date: 2009-08-27; WO2009EP64875 Applic. Date: 2009-11-10

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20110251243A1  Published: 13/Oct/2011

Title: Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime

Applicant/Assignee:

Application No.: 12/944372   Filing Date: 11/Nov/2010

Abstract:

A method of determining a personalised therapeutic regime, comprising: receiving genetic information relating to a patient

determining genetic criteria relevant to a personalised therapeutic regime for the patient using the genetic information

receiving personal information relating to the patient

determining personal criteria relevant to the personalised therapeutic regime using the personal information

and combining the genetic criteria and the personal criteria to determine the personalised therapeutic regime for the patient.

Priority: US2006-530826 Applic. Date: 2006-09-11; US20050715936P Applic. Date: 2005-09-09

Inventor: TUCKER MARK RUPERT [GB]; WALTON ROBERT [GB]; MATTHEWS HUBERT [GB]; MISKIN ANTHONY [GB]


Application No.: US20110256522A1  Published: 20/Oct/2011

Title: ARGININE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS

Applicant/Assignee:

Application No.: 13/028856   Filing Date: 16/Feb/2011

Abstract:

Blood storage and/or rejuvenating compositions that include D-ribose and an arginine (e.g. L-arginine, D-arginine, or a combination thereof) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

Priority: US20100370713P Applic. Date: 2010-08-04; US20100338263P Applic. Date: 2010-02-16

Inventor: ERICSON DANIEL G [US]; THOMPSON JEFFREY A [US]


Application No.: US20110257140A1  Published: 20/Oct/2011

Title: Biomarkers of Mineralocorticoid Receptor Activation

Applicant/Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE)

Application No.: 13/124575   Filing Date: 21/Oct/2009

Abstract:

The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.

Priority: EP20080305728 Applic. Date: 2008-10-24; US20090181821P Applic. Date: 2009-05-28; WO2009EP63832 Applic. Date: 2009-10-21

Inventor: JAISSER FREDERIC [FR]; FARMAN NICOLETTE [FR]; SAINTE-MARIE YANNIS [FR]; LATOUCHE CELINE [AU]; STEENMAN MARJA [FR]


Application No.: US20110257537A1  Published: 20/Oct/2011

Title: BLOOD PRESSURE MONITORING SYSTEM PROVIDING ENHANCED VASCULAR ANEURYSM DETECTION FEATURES AND RELATED METHODS

Applicant/Assignee:

Application No.: 13/087684   Filing Date: 15/Apr/2011

Abstract:

A blood pressure monitoring system may include a plurality of a blood pressure measuring devices each configured to measure blood pressure of a respective extremity of a patient, and a blood pressure monitoring device. The blood pressure monitoring device may include at least one interface device configured to interface with the plurality of blood pressure measuring devices, and a controller coupled to the at least one interface device. The controller may be configured to cooperate with the plurality of blood pressure measuring devices to determine respective blood pressure measurements for each patient extremity, selectively determine differences between the blood pressure measurements, and generate an indication of a probable vascular aneurysm based upon a determined difference between at least two of the blood pressure measurements reaching a vascular aneurysm threshold value.

Priority: US20100324527P Applic. Date: 2010-04-15

Inventor: ALATRISTE ANTHONY [US]


Application No.: US20110263657A1  Published: 27/Oct/2011

Title: DIARYL UREAS FOR TREATING HEART FAILURE

Applicant/Assignee: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 13/001145   Filing Date: 18/Jun/2009

Abstract:

The present invention relates to pharmaceutical compositions for treating, preventing or managing heart failure and/or connected diseases therewith comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.

Priority: EP20080011471 Applic. Date: 2008-06-25; WO2009EP04390 Applic. Date: 2009-06-18

Inventor: ALBRECHT-KUEPPER BARBARA [DE]; SCHAEFER STEFAN [DE]; KIENLEN ELODIE [DE]


Application No.: US20110264025A1  Published: 27/Oct/2011

Title: REGIONAL CITRATE ANTICOAGULATION

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/174217   Filing Date: 30/Jun/2011

Abstract:

A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Priority: US2006-525800 Applic. Date: 2006-09-21; US20050719718P Applic. Date: 2005-09-22

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20110266206A1  Published: 03/Nov/2011

Title: Integrated Blood Specimen Processor

Applicant/Assignee:

Application No.: 13/097975   Filing Date: 29/Apr/2011

Abstract:

A blood specimen processor by means of which blood specimens are collected into a collection tube containing an anticoagulant and a molded buoy of predetermined density between 1.045 and 1.084 with an embedded water swellable o-ring that expands to form a robust seal in a leucocyte density gradient between the buoy's outer surface and tube's inner surface. The buoy is made of a first resin and a second resin, the first resin having a lower density than the second resin, the first resin and the second resin being present in such amounts and relative proportions so that the body has an overall density between 1.045 and 1.084 and preferably, a center of gravity below a geometric center of the body. When the blood specimen contained in the processor is centrifuged, the buoy is thrust through the separating blood and the developing interface of erythrocytes, leucocytes, and plasma. A reproducible gradient develops that builds a reproducible buffy coat ring around the upper trough at the junction of the edge of the separator buoy and the tube wall. The relative proportions of resin are controlled to create a separator buoy of a desired density so that after centrifugation the buffy coat or other cells of interest will be above the water swellable o-ring.

Priority: US20100329339P Applic. Date: 2010-04-29

Inventor: COLEMAN CHARLES M [US]


Application No.: US20110266221A1  Published: 03/Nov/2011

Title: FLOW BALANCING SYSTEM AND METHOD, ESPECIALLY FOR CITRATE

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/185147   Filing Date: 18/Jul/2011

Abstract:

A renal failure therapy system includes a blood pump

a citrate pump

and a control unit configured to automatically control the blood pump and the citrate pump to achieve a citrate flowrate that is based on at least a blood flowrate.

Priority: US2010-763864 Applic. Date: 2010-04-20; US2006-356661 Applic. Date: 2006-02-16; US2003-685724 Applic. Date: 2003-10-15

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]


Application No.: US20110268790A1  Published: 03/Nov/2011

Title: Snake Factor V and Methods of Use Thereof as a Procoagulant

Applicant/Assignee:

Application No.: 13/130378   Filing Date: 23/Nov/2009

Abstract:

Compositions and Methods for the treatment of coagulation disorders using Factor V variants are provided. Preferred disorders include hemophilia A and B.

Priority: US20080116913P Applic. Date: 2008-11-21; WO2009US65515 Applic. Date: 2009-11-23

Inventor: CAMIRE RODNEY [US]; BOS METTINE H A [NL]


Application No.: US20110269159A1  Published: 03/Nov/2011

Title: REAGENTS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/771634   Filing Date: 30/Apr/2010

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]; OMAKOR JOHN EMEGBERO [CA]; MOSS ADAM ROGER [CA]; GUHADOS GANESH [CA]


Application No.: US20110269703A1  Published: 03/Nov/2011

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/128459   Filing Date: 10/Nov/2009

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: US20080113404P Applic. Date: 2008-11-11; US20090237552P Applic. Date: 2009-08-27; WO2009EP64873 Applic. Date: 2009-11-10

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20110269799A1  Published: 03/Nov/2011

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/128460   Filing Date: 10/Nov/2009

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: US20080113413P Applic. Date: 2008-11-11; US20090237559P Applic. Date: 2009-08-27; WO2009EP64874 Applic. Date: 2009-11-10

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20110275666A1  Published: 10/Nov/2011

Title: ACTIVATED BLOOD COAGULATION FACTOR X (FXA) INHIBITOR

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 13/163287   Filing Date: 17/Jun/2011

Abstract:

An object of the present invention is to provide an activated blood coagulation factor X (FXa) inhibitor that reduces the risk of bleeding caused by the treatment of thromboembolism. The present invention provides an oral anticoagulant agent comprising a compound represented by the following formula (1): or a pharmacologically acceptable salt thereof, or a hydrate thereof, as an active ingredient, wherein (A) a factor involved in the risk of bleeding caused by the anticoagulant agent is selected as a dose determinant

(B) a reference value of the dose determinant is set

(C) the dose determinant of a patient in need of administration is measured

and (D) the dose of the anticoagulant agent is selected with the reference value as an index.

Priority: JP20080323578 Applic. Date: 2008-12-19; WO2009JP71016 Applic. Date: 2009-12-17

Inventor: ABIKO TAKASHI [JP]; UCHIYAMA KAZUHISA [JP]; MOTOHASHI TOMOKO [JP]; MATSUDA TOMOKO [JP]; SUDA MIHARU [JP]


Application No.: US20110275935A1  Published: 10/Nov/2011

Title: Methods and Apparatus for Treating or Deterring Injuries to or Disorders of the Brain or Spinal Cord of a Subject

Applicant/Assignee: ZOLL CIRCULATION INC

Application No.: 13/182805   Filing Date: 14/Jul/2011

Abstract:

Methods and apparatus for treating or deterring injuries to or disorders of the brain or spinal cord of a subject. A heat exchange catheter device is inserted into the subject's body and used to cause heating or cooling the subject's cerebrospinal fluid. In some embodiments, the heat exchanger may be positioned within the subject's vasculature so as to heat or cool the flowing blood, thereby resulting in heating or cooling of the cerebrobpinal fluid.

Priority: US2010-853864 Applic. Date: 2010-08-10; US2007-931463 Applic. Date: 2007-10-31; US2007-724075 Applic. Date: 2007-03-13; US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]; GINSBURG ARLENE S [US]


Application No.: US20110277339A1  Published: 17/Nov/2011

Title: METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS UTILIZING MODIFIED SPRAY-DRYING APPARATUS

Applicant/Assignee:

Application No.: 13/165732   Filing Date: 21/Jun/2011

Abstract:

Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Priority: US2004-766651 Applic. Date: 2004-01-27; US2003-353746 Applic. Date: 2003-01-28; US20020354080P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; DEIBELE HEATHER L M [US]; DOBRY DAN E [US]; RAY RODERICK J [US]; SETTELL DANA M [US]; SPENCE KEN R [US]


Application No.: US20110281938A1  Published: 17/Nov/2011

Title: APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/026165   Filing Date: 11/Feb/2011

Abstract:

The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Priority: US2010-858369 Applic. Date: 2010-08-17; US20090234939P Applic. Date: 2009-08-18; US20100353374P Applic. Date: 2010-06-10; US20100366362P Applic. Date: 2010-07-21; US20100367766P Applic. Date: 2010-07-26

Inventor: SCHAUB ROBERT [US]; MCGINNESS KATHLEEN [US]; NELSON JENNIFER [US]; GENGA RYAN [US]; WATERS EMILY [US]; KURZ JEFFREY [US]; DIENER JOHN [US]


Application No.: US20110287094A1  Published: 24/Nov/2011

Title: SPECIFIC TIME-DELAYED BURST PROFILE DELIVERY SYSTEM

Applicant/Assignee: DEXCEL PHARMA TECHNOLOGIES LIMITED

Application No.: 13/196545   Filing Date: 02/Aug/2011

Abstract:

The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent

a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein

and a first inner coating layer, comprising an agent that can cause the dissolution of at least one of the water insoluble components of the outer coating, and optionally a water soluble polymer, such that the insoluble particles in the outer coating, upon absorption of liquid, form channels leading to the inner coating layer, thus enabling the dissolution thereof, whereby the agents contained therein are released to cause the dissolution and/or degradation (destruction) of the outer coating, and the release of the pharmaceutically acceptable active agent from the core of the device.

Priority: US2005-147388 Applic. Date: 2005-06-08

Inventor: PENHASI ADEL [IL]; GOMBERG MILA [IL]; GOMBERG MAXIM [IL]


Application No.: US20110287540A1  Published: 24/Nov/2011

Title: METHOD FOR CONTROLLING PROLIFERATION OF CORD BLOOD HEMATOPOIETIC STEM CELLS AND USE THEREOF

Applicant/Assignee: JMS CO., LTD

Application No.: 13/146613   Filing Date: 22/Jan/2010

Abstract:

The present invention provides a method for controlling the proliferation and differentiation of cord blood-derived hematopoietic stem cells with excellent safety when proliferating them by culturing. The hematopoietic stem cells are inoculated into a medium containing a sonicated liquid component of cord blood. The proliferation and differentiation of the cord blood hematopoietic stem cells can be inhibited in the presence of the sonicated liquid component of cord blood. On the contrary, the proliferation of cord blood hematopoietic stem cells can be accelerated by inoculating the hematopoietic stem cells into a medium containing a non-sonicated liquid component of cord blood. Thus, according to the present invention, by using serum derived from cord blood, it is possible to regulate the inhibition of the proliferation and differentiation of cord blood hematopoietic stem cells and the acceleration of the proliferation of the same as desired.

Priority: JP20090015639 Applic. Date: 2009-01-27; JP20100006277 Applic. Date: 2010-01-14; WO2010JP50795 Applic. Date: 2010-01-22

Inventor: HIRAI SATOSHI [JP]; OGATA KASUMI [JP]


Application No.: US20110288464A1  Published: 24/Nov/2011

Title: REGIONAL CITRATE ANTICOAGULATION

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/174192   Filing Date: 30/Jun/2011

Abstract:

A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Priority: US2006-525800 Applic. Date: 2006-09-21; US20050719718P Applic. Date: 2005-09-22

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20110294902A1  Published: 01/Dec/2011

Title: PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS

Applicant/Assignee:

Application No.: 13/208305   Filing Date: 11/Aug/2011

Abstract:

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Priority: US2000-742785 Applic. Date: 2000-12-20; US19990171841P Applic. Date: 1999-12-23

Inventor: CURATOLO WILLIAM J [US]; SHANKER RAVI M [US]; BABCCCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; LORENZ DOUGLAS A [US]


Application No.: US20110295152A1  Published: 01/Dec/2011

Title: PUNCTURE METHOD, INCISION NEEDLE, PUNCTURE NEEDLE, NEEDLE CAP AND INSTRUMENT FOR BLOOD PURIFICATION TREATMENT

Applicant/Assignee: NEXTIER CORPORATION, ASAHI KASEI KURARAY MEDICAL CO., LTD

Application No.: 13/115275   Filing Date: 25/May/2011

Abstract:

The present invention is a method of puncturing a shunt blood vessel, using a incision needle having a pointed extremity that protrudes apically from a hypothetical angled plane formed by cutting straight through the tip of the needle at an angle, wherein the pointed extremity of the incision needle is inserted into a shunt blood vessel, thereby forming a reverse U-shaped incision on the surface of the shunt blood vessel, with the apex of the incision being on the bottom side in the direction of insertion.

Priority: JP20100119634 Applic. Date: 2010-05-25; JP20100126867 Applic. Date: 2010-06-02; JP20100126885 Applic. Date: 2010-06-02

Inventor: SASAKI MASATOMI [JP]; SHINZATO TORU [JP]; MARUYAMA YASUYO [JP]; SHIONOYA YUKIE [JP]


Application No.: US20110297048A1  Published: 08/Dec/2011

Title: FOAMING AGENT

Applicant/Assignee: GENESIS GLOBAL LIMITED

Application No.: 13/142648   Filing Date: 30/Dec/2009

Abstract:

A foaming agent solution, cement material and concrete replacement product are described which include blood hydrolysates. The blood hydrolysates may be present in the foaming agent solution in the range 5-30% by volume of the solution.

Priority: GB20080023721 Applic. Date: 2008-12-31; WO2009GB02975 Applic. Date: 2009-12-30

Inventor: GEORGE ANTHONY S M [GB]


Application No.: US20110300608A1  Published: 08/Dec/2011

Title: NUCLEIC ACID ISOLATION IN PRESERVED WHOLE BLOOD

Applicant/Assignee: STRECK, INC

Application No.: 12/678190   Filing Date: 17/Sep/2008

Abstract:

A method for isolating nucleic acids is disclosed, wherein a sample having nucleic acid containing starting material is fixed, lysed, and treated to remove unwanted contaminants. The initial fixing of the sample aids in maintaining the structure and integrity of the isolated DNA and reduces the incidence of end product contaminants and DNA shearing.

Priority: US20070974115P Applic. Date: 2007-09-21; WO2008US76590 Applic. Date: 2008-09-17

Inventor: RYAN WAYNE L [US]; CHAN KATE CHAO-WEI [US]


Application No.: US20110301180A1  Published: 08/Dec/2011

Title: Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration

Applicant/Assignee: STANFORD UNIVERSITY

Application No.: 13/093825   Filing Date: 25/Apr/2011

Abstract:

It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

Priority: US20100327613P Applic. Date: 2010-04-23

Inventor: COLLMAN JAMES P [US]; HERRMANN PAUL CLIFFORD [US]; TYVOLL DAVID ALVIN [US]; DECREAU RICHARD [FR]; BULL BRIAN STANLEY [US]; BARILE CHRISTOPHER JEFFREY [US]


Application No.: US20110301522A1  Published: 08/Dec/2011

Title: DIALYSIS CATHETER

Applicant/Assignee:

Application No.: 13/108154   Filing Date: 16/May/2011

Abstract:

A dialysis catheter including a first portion having an outer wall having a first diameter, an elongated distal portion having a second diameter smaller than the first diameter, and a transition region between the first portion and distal portion. A first longitudinally extending venous lumen is configured to deliver blood. First and second independent longitudinally extending arterial lumens are configured to withdraw blood from a patient. The venous lumen and arterial lumen have first and second regions each positioned a first distance from the outer wall of the catheter and a third region positioned a second shorter distance from the outer wall of the catheter to form an arch shaped wall portion progressively increasing in thickness from the third region toward the first region and from the third region to the second region.

Priority: US20100352195P Applic. Date: 2010-06-07

Inventor: DEFONZO STEPHAN A [US]


Application No.: US20110306070A1  Published: 15/Dec/2011

Title: MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/815132   Filing Date: 14/Jun/2010

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immuno sensor.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]


Application No.: US20110306552A1  Published: 15/Dec/2011

Title: PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/840725   Filing Date: 21/Jul/2010

Abstract:

The present invention relates to new pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof

Priority: US20090229096P Applic. Date: 2009-07-28

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Application No.: US20110306853A1  Published: 15/Dec/2011

Title: Body fluid sampling/fluid delivery device

Applicant/Assignee:

Application No.: 13/052887   Filing Date: 21/Mar/2011

Abstract:

A body fluid sampling or fluid delivery system includes a polymeric support and an array of polymeric microneedles coupled to the support, each of a microneedle having a height of 500 to 2000 [mu]m and a tapering angle of 60 to 90 DEG . A plurality of polymeric microchannels are provided with being associated with a microneedle. The plurality of polymeric microchannels are integrally formed with the array of polymeric microneedles without bonding. At least one polymeric reservoir is coupled to the plurality of microchannels.

Priority: US20100315736P Applic. Date: 2010-03-19

Inventor: BLACK MICHAEL DARRYL [US]; CHAMBERS ANITA MARGARETTE [US]; CHAMBERS RICHARD [US]; OKULAN NIHAT [US]


Application No.: US20110311769A1  Published: 22/Dec/2011

Title: ANTIFOULING SURFACES, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: 13/164600   Filing Date: 20/Jun/2011

Abstract:

Disclosed herein is an article comprising a substrate

a polymer disposed upon the substrate

the polymer having a number average molecular weight of about 2,000 to about 5,000 grams per mole

where each polymer is separated from a neighboring polymer by an average distance of 2.5 Angstroms to 5,000 Angstroms. Disclosed herein is a method comprising disposing upon a substrate a polymer

the polymer having a number average molecular weight of 2,000 to about 5,000 grams per mole.

Priority: US20100357254P Applic. Date: 2010-06-22

Inventor: CHEN JIUN-JENG [US]; BRENNAN ANTHONY B [US]


Application No.: US20110312015A1  Published: 22/Dec/2011

Title: RAPID THROMBOCHEK TEST KIT BASED ON WHOLE BLOOD SCREENING TEST TO DETECT PLATELET HYPERAGGREGATION AT A TEMPERATURE OF 37 C IN THE CLINICAL LABORATORY

Applicant/Assignee:

Application No.: 13/111938   Filing Date: 19/May/2011

Abstract:

The new RAPID THROMBOCHEK TEST KIT is based on thrombochek screening test for measurement of hyperaggregable platelets in whole blood, which may be present either in form of circulating platelet aggregates, spontaneously aggregating platelets or reacting to weak agonist of platelet aggregation in low concentration-all together, in order to investigate thrombotic tendencies and to assess the efficacy of antithrombotic therapy all measured with help of hematology cell counter and magnetic stirrer at 37 DEG C. of temperature. This is compared to the other existing microscopic method and shows 0.97% correlation. RAPID THROMBOCHEK TEST KIT based on the above methodology is to be used with the aid of an automated hematology analyser and is made available for routine clinical and office laboratory use.

Priority: IN2008MU02440 Applic. Date: 2008-11-19; WO2008IN00785 Applic. Date: 2008-11-25

Inventor: VELASKAR DILIP SHRINIVAS [IN]


Application No.: US20110312020A1  Published: 22/Dec/2011

Title: Ex-Vivo Passive Protection Bacteremia Assay

Applicant/Assignee:

Application No.: 13/133907   Filing Date: 10/Dec/2009

Abstract:

The present disclosure provides methods for assessing bactericidal antibodies in a biological sample by use of human fresh whole blood from a non-immune human as a reaction medium for the assay.

Priority: US20080139988P Applic. Date: 2008-12-22; WO2009US67515 Applic. Date: 2009-12-10

Inventor: GRANOFF DAN M [US]; WELSCH JO ANNE [US]; PLESTED JOYCE [US]


Application No.: US20110312067A1  Published: 22/Dec/2011

Title: DIALYSIS DEVICE FOR SEPARATING PATHOGENS FROM A BIOLOGICAL SAMPLE

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149974   Filing Date: 01/Jun/2011

Abstract:

A dialysis device to separate pathogens from a biological sample, the dialysis device having a first channel for receiving the biological sample, a second channel, and, a plurality of apertures, wherein, the second channel is fluidically connected to the first channel via the apertures such that the pathogens flow from the first channel to the second channel and larger constituents in the biological sample remain in the first channel.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312068A1  Published: 22/Dec/2011

Title: DIALYSIS DEVICE FOR SEPARATING NUCLEATED CELLS IN A BIOLOGICAL SAMPLE FROM OTHER CONSTITUENTS

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149976   Filing Date: 01/Jun/2011

Abstract:

A dialysis device to separate nucleated cells in a biological sample from smaller constituents, the dialysis device having a first channel for receiving the biological sample, a second channel, and, a plurality of apertures, wherein, the second channel is fluidically connected to the first channel via the apertures, the apertures being smaller than the nucleated cells such that the smaller constituents flow from the first channel to the second channel and the nucleated cells in the biological sample remain in the first channel

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312071A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH LARGE CHANNELS FOR CELL TRANSPORT AND SMALL CHANNELS SUITABLE FOR BIOCHEMICAL PROCESSES

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149913   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device for molecular diagnostic analysis of a biological sample containing cells, the microfluidic device having a supporting substrate, a plurality of microsystems technology (MST) channels each with a cross-sectional area between 1 square micron and 400 square microns for biochemical processing of constituents within the biological sample, and, a plurality of cell transport channels, each with a cross-sectional area greater than 400 square microns for receiving the biological sample and transporting cells within the biological sample to predetermined sites in the MST channels.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312072A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH SURFACE MICRO-MACHINED CHIPS AND INTERCONNECTING CAP

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149916   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device for diagnostic analysis of a sample fluid, the microfluidic device having a plurality of lab-on-a-chip (LOC) devices each having a supporting substrate and a microsystems technology (MST) layer for processing the sample fluid, and, a cap interconnecting the plurality of LOC devices, the cap having a cap channel for establishing fluid communication between the MST layers on at least two of the LOC devices.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312073A1  Published: 22/Dec/2011

Title: MICROFLUIDIC TEST MODULE INCORPORATING SURFACE MICRO-MACHINED CHIPS AND INTERCONNECTING CAP

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149919   Filing Date: 01/Jun/2011

Abstract:

A test module having a casing for hand held portability, a receptacle for receiving a sample fluid, and, a microfluidic device in fluid communication with the inlet, the microfluidic device having a plurality of lab-on-a-chip (LOC) devices and a cap in engagement with each of the plurality of LOC devices, wherein, the cap is configured to establish fluid communication between at least two of the LOC devices.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312074A1  Published: 22/Dec/2011

Title: MICROFLUIDIC TEST MODULE WITH SAMPLE RECEPTACLE

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149922   Filing Date: 01/Jun/2011

Abstract:

A test module having a receptacle for receiving an unprocessed biological sample through an opening, a cover movable between open and closed positions, the cover exposing the opening when in the open position and closing the opening when in the closed position, and, a microfluidic device for processing the biological sample, the microfluidic device having a sample inlet, wherein, the receptacle is configured for fluid communication with the sample inlet such that the biological sample flows to the sample inlet by capillary action.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312526A1  Published: 22/Dec/2011

Title: METHOD OF ANALYSING THE NUCLEIC ACID CONTENT OF A BLOOD SAMPLE

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150078   Filing Date: 01/Jun/2011

Abstract:

A method of analyzing the nucleic acid content of a blood sample, the method comprising the steps of: providing a test module with an outer casing configured for handheld portability, the outer casing having a receptacle for receiving blood, the test module having a lysis section mounted in the outer casing for lysing cells and organisms in the blood to release the genetic material therein, a hybridization section with an array of probes for hybridization with target nucleic acid sequences in the genetic material, and circuitry for sensing which of the probes have hybridized and generating hybridization data, providing a test module reader for reading the hybridization data from the test module, inserting a blood sample in the receptacle, interfacing the test module with the test module reader, wherein, the test module reader analyses the nucleic acid content from the hybridization data.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]; MOINI ALIREZA [AU]


Application No.: US20110312548A1  Published: 22/Dec/2011

Title: TEST MODULE WITH DIFFUSIVE MIXING IN SMALL CROSS SECTIONAL AREA MICROCHANNEL

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149908   Filing Date: 01/Jun/2011

Abstract:

A test module for analysis of genetic material in a biological sample, the test module having an outer casing with an inlet for receiving the sample, a diffusion mixing section for diffusive mixing of the sample with at least one other liquid, the diffusion mixing section having a microchannel defining a flow-path for a combined flow of the sample and the at least one other liquid, wherein, the channel cross section transverse to the flow direction is less than 100,000 square microns.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312593A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH INCUBATOR HAVING TWO-DIMENSIONAL CONTROL OF INPUT HEAT FLUX

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150147   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device having an inlet for receiving a fluid, an incubation section having a microchannel configured to have a plurality of mutually parallel, adjacent channel sections, and a plurality of elongate heaters positioned end to end along each of the channel sections, wherein, each of the heaters are independently operable for two-dimensional control of heat flux density to the incubation section.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]; FACER GEOFFREY RICHARD [AU]


Application No.: US20110312596A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH SURFACE TENSION VALVE AT REAGENT RESERVOIR OUTLET

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150154   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device for processing a fluid sample, the microfluidic device having a reservoir for containing a reagent, and, a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus such that the reagent flows out of the reagent reservoir.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312598A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH REAGENT MIXING PROPORTIONS DETERMINED BY OUTLET VALVE NUMBERS

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150162   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device for testing a fluid, the microfluidic device having an inlet for receiving the fluid, a reservoir containing a reagent, a flow-path extending from the inlet, a valve assembly for establishing a fluid connection between the flow-path and the reservoir, the valve assembly having a plurality of outlet valves and a plurality of channels from the reservoir to the flow-path, wherein during use, a number of the outlet valves open such that the reagent flows through the valve assembly to the flow-path to combine with the fluid from the inlet to produce a combined flow having a proportion of the reagent, the proportion of the reagent in the combined flow being determined by the number of the outlet valves opened.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312628A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH MST LAYER AND OVERLYING CAP

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149900   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device having a supporting substrate, a microsystems technologies (MST) layer on the supporting substrate, a cap overlying the MST layer, the cap having a plurality of fluidic connections between the cap and the MST layer for fluid flow from the MST layer to the cap and fluid flow from the cap to the MST layer.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312632A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH PCR SECTION AND DIFFUSION MIXER

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149907   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device having a sample inlet for receiving a sample of biological material having nucleic acid sequences, a polymerase chain reaction (PCR) section for amplifying the nucleic acid sequences, a reagent reservoir containing a reagent, and, a diffusion mixing section for mixing the nucleic acid sequences with the reagent, the diffusion mixing section having a microchannel defining a tortuous flow-path having a length sufficient for diffusive mixing of the reagent and the sample, wherein during use, the sample flows from the sample inlet to the PCR section via the diffusion mixing section.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: FACER GEOFFREY RICHARD [AU]; SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312681A1  Published: 22/Dec/2011

Title: LOC DEVICE WITH DIALYSIS SECTION FOR REMOVING ERYTHROCYTES FROM BLOOD

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149983   Filing Date: 01/Jun/2011

Abstract:

A lab-on-a-chip (LOC) device for analyzing leukocytes in a blood sample, the LOC device having a supporting substrate, an inlet for receiving a sample of blood, a dialysis section for separating erythrocytes from leukocytes in the blood, and, a microsystems technology (MST) layer for analyzing the leukocytes, wherein, the inlet, the dialysis section and the MST layer are all supported on the supporting substrate.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: BOULTER NICOLA [AU]; SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312746A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH CHEMICAL LYSIS SECTION

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150099   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device for lysing cells in a fluid, the microfluidic device having an inlet for receiving a fluid containing cells, a lysis reagent reservoir containing a lysis reagent and having an outlet valve, and, a lysis section in fluid communication with the inlet for holding the fluid during lysis of the cells, wherein, the outlet valve is upstream of the lysis section and configured to open as the fluid flows into the lysis section thereby adding the lysis reagent to the fluid.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]; FACER GEOFFREY RICHARD [AU]


Application No.: US20110312749A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH THERMAL LYSIS SECTION

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150104   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device for lysing cells in a fluid, the microfluidic device having an inlet channel for receiving a fluid containing cells, a lysis section in fluid communication with the inlet channel for holding the fluid during lysis of the cells, and, a lysis heater for heating the fluid in the lysis section such that the cells lyse, wherein, the inlet channel is configured for filling the lysis section by capillary action.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; FACER GEOFFREY RICHARD [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312755A1  Published: 22/Dec/2011

Title: TEST MODULE WITH CHEMICAL LYSIS SECTION

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150111   Filing Date: 01/Jun/2011

Abstract:

A test module for lysing cells in a fluid, the test module having an outer casing with receptacle for receiving a fluid containing cells, a lysis reagent reservoir containing a lysis reagent and having an outlet valve, and, a lysis section in fluid communication with the receptacle for holding the fluid during lysis of the cells, wherein, the outlet valve is upstream of the lysis section and configured to open as the fluid flows into the lysis section thereby adding the lysis reagent to the fluid.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]; FACER GEOFFREY RICHARD [AU]


Application No.: US20110312758A1  Published: 22/Dec/2011

Title: TEST MODULE WITH THERMAL LYSIS SECTION

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150114   Filing Date: 01/Jun/2011

Abstract:

A test module for lysing cells in a fluid, the test module having an outer casing with receptacle for receiving a sample that is a fluid containing cells, a lysis section in fluid communication with the receptacle for holding the fluid during lysis of the cells, and, a lysis heater for heating the fluid in the lysis section to lyse cells, wherein, the test module is configured for drawing the fluid from the receptacle to the lysis section by capillary action.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; FACER GEOFFREY RICHARD [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312761A1  Published: 22/Dec/2011

Title: TEST MODULE FOR CHEMICALLY AND THERMALLY LYSING CELLS

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150117   Filing Date: 01/Jun/2011

Abstract:

A test module for lysing cells in a fluid, the test module having an outer casing with receptacle for receiving a fluid containing cells, a lysis reagent reservoir containing a lysis reagent and having a valve, and, a lysis section in fluid communication with the receptacle for holding the fluid during lysis of the cells, the lysis section having a lysis heater for heating the fluid in the lysis section, wherein, the valve is upstream of the lysis section and configured to open as the fluid flows into the lysis section thereby adding the lysis reagent to the fluid.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: FACER GEOFFREY RICHARD [AU]; SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312774A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE FOR DIFFUSIVE MIXING IN SMALL CROSS SECTIONAL AREA MICROCHANNEL

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150155   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device having a supporting substrate, a microsystems technologies (MST) layer on the supporting substrate, the MST layer being configured to combine at least two liquids to form a flow of combined liquids, the MST layer having a diffusion mixing section for diffusive mixing of the at least two liquids, the mixing section having a microchannel defining a flow-path for the combined liquids, wherein, the channel cross section transverse to the flow direction is less than 100,000 square microns.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312798A1  Published: 22/Dec/2011

Title: TEST MODULE WITH INBUILT LANCET

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150210   Filing Date: 01/Jun/2011

Abstract:

A test module for processing and analyzing a blood sample, the test module having an outer casing with a receptacle for receiving blood, functional sections for processing and analyzing the sample, and, a lancet for collecting the blood sample from a patient.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312821A1  Published: 22/Dec/2011

Title: MICROFLUIDIC DEVICE WITH WASTE STORAGE

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150250   Filing Date: 01/Jun/2011

Abstract:

A microfluidic device having a supporting substrate, a microsystems technologies (MST) layer on the supporting substrate for analyzing a fluid, and, a waste reservoir for storage of waste material separated from the fluid.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312824A1  Published: 22/Dec/2011

Title: TEST MODULE WITH WASTE STORAGE INCORPORATING POROUS ELEMENT

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/150253   Filing Date: 01/Jun/2011

Abstract:

A test module for analyzing fluid containing target nucleic acid sequences, the test module having a casing for hand-held portability, the casing having a receptacle for receiving the fluid, an array of probes for hybridization with target nucleic acid sequences to form probe-target hybrids, and, a waste accumulator for storage of waste material separated from the fluid, wherein, the waste accumulator has a waste reservoir and a porous element to draw the waste material into the waste reservoir by capillary action.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: AZIMI MEHDI [AU]; SILVERBROOK KIA [AU]


Application No.: US20110312841A1  Published: 22/Dec/2011

Title: FABRICATION SYSTEM FOR LAB-ON-A-CHIP (LOC) DEVICES WITH DIFFERING APPLICATION SPECIFIC FUNCTIONALITY

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149891   Filing Date: 01/Jun/2011

Abstract:

A fabrication system for lab-on-a-chip (LOC) devices with differing application specific functionality, the fabrication system having a database of different functional categories, each of the functional categories having a plurality of functional section designs, means for selecting a compilation of the functional section designs to generate a LOC design in accordance with a specific functionality intended for LOC devices fabricated in accordance with the LOC design, and, a MST (microsystems technology) fabrication facility for fabricating LOC devices in accordance with the LOC design, wherein, the functional section designs in any one of the functional categories are functionally compatible with at least one of the functional section designs in the other functional categories.

Priority: US20100356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20110312991A1  Published: 22/Dec/2011

Title: ACTIVATED BLOOD COAGULATION FACTOR INHIBITOR

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 13/181596   Filing Date: 13/Jul/2011

Abstract:

An object of the present invention is to provide a novel salt form of a compound that exhibits an inhibitory effect on activated blood coagulation factor X, and is useful as a preventive and/or therapeutic drug for thrombotic diseases, and crystals thereof. The present invention provides N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide tartrate and crystals thereof, as a novel salt form of N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide and crystals thereof.

Priority: JP20090004904 Applic. Date: 2009-01-13; WO2010JP50128 Applic. Date: 2010-01-08

Inventor: ONO MAKOTO [JP]


Application No.: US20110313514A1  Published: 22/Dec/2011

Title: Drug-eluting stent

Applicant/Assignee: JAPAN STENT TECHNOLOGY CO., LTD

Application No.: 13/137560   Filing Date: 25/Aug/2011

Abstract:

A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).

Priority: JP20090048577 Applic. Date: 2009-03-02; WO2010JP52975 Applic. Date: 2010-02-25

Inventor: OMURA IKUO [JP]; JIN ZHEN YU [JP]


Application No.: US20110315583A1  Published: 29/Dec/2011

Title: INTRAVASCULAR INDWELLING CATHETER LOCK SOLUTION CONTAINING WEAK ACID AND CONTAINER CONTAINING THE SAME

Applicant/Assignee: JMS CO., LTD

Application No.: 13/133123   Filing Date: 05/Dec/2008

Abstract:

A catheter lock solution which is a catheter lock preparation having a bacteriostatic property at physiological osmotic pressure without practically containing a bacteriostatic component such as a preservative, an antimicrobial agent, or an antibiotic and having high safety, characterized in that the preparation contains a weak acid having an acid dissociation constant (pKa) of 3.0 to 6.5 as a buffer, a pH of the solution is less than 6.0, preferably from 3.0 to about 5.5, an osmotic pressure ratio is from 0.5 to 3.0, and a pH change (variation) can be suppressed to less than the 6.0 with the weak acid, and a container containing the catheter lock solution.

Priority: WO2008JP72186 Applic. Date: 2008-12-05

Inventor: KIMURA YUKO [JP]; SUZUKI KOJI [JP]; IWATA MINORU [JP]; IWAMOTO SUMIKA [JP]; YAMAMOTO TAKASHI [JP]


Application No.: US20110318404A1  Published: 29/Dec/2011

Title: Wound Dressing, Methods and Apparatus For Making Same and Storage and Use Thereof

Applicant/Assignee:

Application No.: 13/145205   Filing Date: 27/Jan/2010

Abstract:

Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.

Priority: US20090147513P Applic. Date: 2009-01-27; WO2010IL00066 Applic. Date: 2010-01-27

Inventor: KUSHNIR ALON [IL]; KUSHNIR IGAL [IL]


Application No.: US20110319728A1  Published: 29/Dec/2011

Title: BLOOD PARAMETER SENSOR AND FLOW CONTROL SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT

Applicant/Assignee: EDWARDS LIFESCIENCES CORPORATION

Application No.: 12/826542   Filing Date: 29/Jun/2010

Abstract:

A system is provided for sensing a blood parameter, such as an analyte, in a patient's vasculature. The system includes a vascular access device, a parameter sensor, a pressure sensor and a flow control device. The vascular access device supports the parameter sensor within the vasculature of the patient and includes an internal passageway for drawing samples onto and calibrating the parameter sensor. The pressure sensor is within the internal passageway. The flow control device modulates sample draw, calibration and flushing fluid flows to prevent or remove clots based on communication with the pressure sensor. Advantageously, the dynamic, adaptive modulation of flow reduces flushing and other cycle times while at the same time improving clot flushing. As another advantage, this enables reduction or elimination of the use of heparin and other anticoagulant components in the solution supplied for flushing and/or calibration.

Priority:

Inventor: PETISCE JAMES [US]; JACKSON EMILY [US]; CARLIN GREGORY J [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Patent Applications published in 2012
US Patent Applications published in 2010
Provisional Patents in Blood Anticlot Technology, Medications and
Medical Devices Published in 2011